




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 403/04, A61K 31/53, C07D 401/04, 251/18, 417/04, 413/10, 401/12, 409/10, 407/10, 407/04, 409/04, 409/06, 405/04, 453/02, 401/10		A1	(11) International Publication Number: WO 99/31088
			(43) International Publication Date: 24 June 1999 (24.06.99)
(21) International Application Number: PCT/US98/26369		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 11 December 1998 (11.12.98)			
(30) Priority Data: 08/990,119 12 December 1997 (12.12.97) US 09/209,396 10 December 1998 (10.12.98) US			
(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD O377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).			
(72) Inventors: HENKIN, Jack; 1370 Lincoln Avenue South, Highland Park, IL 60035 (US). DAVIDSON, Donald, J.; 4835 Kingsway West, Gurnee, IL 60031 (US). SHEPPARD, George, S.; 315 Laurel Avenue, Wilmette, IL 60091 (US). WOODS, Keith, W.; 200 Red Top Drive #303, Libertyville, IL 60048 (US). MCCROSKEY, Richard, W.; 1038 S. Talcot Drive, Waukegan, IL 60085 (US).			
(74) Agents: STEELE, Gregory, W. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).			

(54) Title: TRIAZINE ANGIOGENESIS INHIBITORS



(57) Abstract

Compounds having Formula (I) or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting angiogenesis in a mammal.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon			PT	Portugal		
CN	China	KR	Republic of Korea	RO	Romania		
CU	Cuba	KZ	Kazakhstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

TRIAZINE ANGIOGENESIS INHIBITORS

Technical Field

The present invention relates to substituted triazines which are useful for treating pathological states which arise from or are exacerbated by angiogenesis, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting angiogenesis in a mammal.

Background of The Invention

Angiogenesis, the process by which new blood vessels are formed, is essential for normal body activities including reproduction, development and wound repair. Although the process is not completely understood, it is believed to involve a complex interplay of molecules which regulate the growth of endothelial cells (the primary cells of capillary blood vessels). Under normal conditions, these molecules appear to maintain the microvasculature in a quiescent state (i.e. one of no capillary growth) for prolonged periods which may last for as long as weeks or, in some cases, decades. When necessary (such as during wound repair), these same cells can undergo rapid proliferation and turnover within a 5 day period (Folkman, J. and Shing, Y., *The Journal of Biological Chemistry*, 267(16), 10931-10934, (1992) and Folkman, J. and Klagsbrun, M., *Science*, 235, 442-447 (1987)).

Although angiogenesis is a highly regulated process under normal conditions, many diseases (characterized as angiogenic diseases) are driven by persistent unregulated angiogenesis. Otherwise stated, unregulated angiogenesis may either cause a particular disease directly or exacerbate an existing pathological condition. For example, ocular neovascularization has been implicated as the most common cause of blindness and dominates approximately twenty eye diseases. In certain existing conditions, such as arthritis, newly formed capillary blood vessels invade the joints and destroy cartilage. In diabetes, new capillaries formed in the retina invade the vitreous, bleed, and cause blindness. Growth and metastasis of solid tumors are also dependent on angiogenesis (Folkman, J., *Cancer Research*, 46, 467-473 (1986), Folkman, J., *Journal of the National Cancer Institute*, 82, 4-6 (1989)). It has been shown, for example, that tumors which enlarge to greater than 2 mm must obtain their own blood supply and do so by inducing the growth of new capillary blood vessels. Once these new blood vessels become embedded in the tumor, they provide a means for tumor cells to enter the circulation and

metastasize to distant sites such as liver, lung or bone (Weidner, N., et al., *The New England Journal of Medicine*, 324(1), 1-8 (1991)).

Several angiogenesis inhibitors are currently under development for use in treating angiogenic diseases (Gasparini, G. and Harris, A. L., *J. Clin. Oncol.*, 13(3): 765-782,


5 1995), but there are disadvantages associated with these compounds. Suramin, for example, is a potent angiogenesis inhibitor but causes severe systemic toxicity in humans at doses required for antitumor activity. Compounds such as retinoids, interferons and antiestrogens are relatively safe for human use but have weak antiangiogenic effects. Irsogladine, an anti-tumor drug with low toxicity, has only weak anti-angiogenic effects.

10 Thus there is still a need for compounds useful in treating angiogenic diseases in mammals.

Summary of The Invention

In one embodiment of the present invention are disclosed compounds having

15 Formula I:



or pharmaceutically acceptable salts or prodrugs thereof, wherein

R₁, R₂, R₃, and R₄ are independently selected from the group

20 consisting of hydrogen, C₁-C₂₀ alkyl, and C₁-C₂₀ alkanoyl; or

R₁ and R₂ together with the nitrogen atom to which they are attached form a ring independently selected from the group consisting of morpholine, piperidine, piperazine, and pyrrolidine; or

25 R₃ and R₄ together with the nitrogen atom to which they are attached form a ring independently selected from the group consisting of morpholine, piperidine, piperazine, and pyrrolidine;

A is selected from the group consisting of heterocycle, (heterocycle)-C₁-C₂₀-alkyl, C₃-C₁₀ cycloalkyl, C₆-C₁₅ spiroalkyl, and -B-L-Y;

B and Y are independently aryl, C₃-C₁₀ cycloalkyl,

30 C₄-C₁₀ cycloalkenyl, heterocycle, or C₆-C₁₅ spiroalkyl;

L is a covalent bond, -C(=W)-, C₁-C₂₀ alkylene, -NR₅-, -NR₆C(X)NR₇-, C₂-C₂₀ alkynylene, C₂-C₂₀ alkenylene, -O-, -S(O)₁-, -NR₆C(X)-, -C(X)NR₆-, -NR₆SO₂NR₇-, -NR₆SO₂- , -SO₂NR₆-, or -O(CR₁R₂)-;

R₅ is hydrogen, C₁-C₂₀ alkyl, C₁-C₂₀ alkanoyl, and C₁-C₂₀ arylalkyl;

R₆ and R₇ are independently hydrogen, C₁-C₂₀ alkyl, and aryl-C₁-C₂₀-alkyl;


R₁ and R₂ are previously defined;

W is O, S, or (=N-O-R₆);

X is O or S;

t is 0-2;

each L is shown with its left end attached to B and its right end attached to Y; and at each occurrence, aryl, cycloalkyl, cycloalkenyl, heterocycle, spiroalkyl, alkylene, and (heterocycle)alkyl may be optionally substituted with 1-3 substituents independently selected from C₁-C₂₀ alkoxy, C₁-C₂₀ alkyl, amino, aryl, azido, cyano, halo, C₁-C₂₀ haloalkyl, heterocycle, nitro, or R₁₀ and R₁₁ wherein R₁₀ and R₁₁ together are



wherein A and D are independently oxygen or S(O)_t and n is 2-3,

with the proviso that when B and Y are unsubstituted phenyl and L is a covalent bond, then at least one of R₁, R₂, R₃, and R₄ is other than hydrogen, and

with the proviso that when L is a covalent bond and one of B or Y is unsubstituted imidazole and the other is unsubstituted phenyl, then at least one of R₁, R₂, R₃, and R₄ is other than hydrogen.

In another embodiment of the invention are disclosed methods of treating diseases comprising administering an effective amount of a compound having Formula I.

In yet another embodiment of the invention are disclosed pharmaceutical compositions containing compounds of Formula I.

Compounds of this invention include, but are not limited to, a compound selected from the group consisting of:

6-[1-(diphenylmethyl)-3-azetidinyl]-1,3,5-triazine-2,4-diamine,

6-(1-phenyl-4-piperidinyl)-1,3,5-triazine-2,4-diamine,

trans-6-(4-phenylcyclohexyl)-1,3,5-triazine-2,4-diamine,

6-[3-(1H-pyrrol-1-yl)phenyl]-1,3,5-triazine-2,4-diamine,

cis/trans-6-(3-phenylcyclobutyl)-1,3,5-triazine-2,4-diamine,

6-[1,1'-biphenyl]-2-yl-1,3,5-triazine-2,4-diamine,

6-(4'-nitro[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,

6-[4-(4-pentylcyclohexyl)phenyl]-1,3,5-triazine-2,4-diamine,

6-(4-phenoxyphenyl)-1,3,5-triazine-2,4-diamine,

N-cyclohexyl-N'-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]urea,

(4,6-diamino-1,3,5-triazine-2-yl)phenylmethenone,

N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]-N'-phenyl urea,

6-(1,4-dioxa-8-azaspiro[4,5]dec-8-yl)-1,3,5-triazine-2,4-diamine,

6-(4'-pentyl[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
6-[4'-(pentyloxy)[1,1'-biphenyl]-4-yl]-1,3,5-triazine-2,4-diamine,
6-(6-methoxy-2-benzothiazolyl)-1,3,5-triazine-2,4-diamine,
6-(4'-amino[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
5 6-[4-(5-oxazolyl)phenyl]-1,3,5-triazine-2,4-diamine,
6-[4-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]-1,3,5-triazine-2,4-diamine,
4'-(4,6-diamino-1,3,5-triazine-2-yl)[1,1'-biphenyl]-4-carbonitrile,
6-(4'-methoxy[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
6-(4'-fluoro[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine
10 *N*-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]benzenesulfonamide,
6-[1-([1,1'-biphenyl]-4-yl)-4-piperidinyl]-1,3,5-triazine-2,4-diamine,
N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]-2-naphthalenesulfonamide,
2,5-dichloro-*N*-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]benzenesulfonamide,
6-(1-phenylcyclohexyl)-1,3,5-triazine-2,4-diamine,
15 6-[1-(4-methoxyphenyl)-4-piperidinyl]-1,3,5-triazine-2,4-diamine,
6-[2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]-1,3,5-triazine-2,4-diamine,
6-[1-(4-methoxyphenyl)cyclohexyl]-1,3,5-triazine-2,4-diamine,
6-[4-(2-thienyl)phenyl]-1,3,5-triazine-2,4-diamine,
6-[4-(phenylethynyl)phenyl]-1,3,5-triazine-2,4-diamine,
20 *N,N'*-(6-[1,1'-biphenyl]-4-yl-1,3,5-triazin-2,4-diyl)bis[acetamide],
N-(4-amino-6-[1,1'-biphenyl]-4-yl-1,3,5-triazin-2-yl)acetamide,
N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]-1-naphthalenesulfonamide,
6-(4'-azido[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
6-[4-(4-morpholinylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine,
25 6-[4-(2-furanyl)phenyl]-1,3,5-triazine-2,4-diamine,
N,N'-[6-(4-phenoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[acetamide],
N-[4-amino-6-(4-phenoxyphenyl)-1,3,5-triazin-2-yl]acetamide,
6-(5-phenyl-2-furanyl)-1,3,5-triazine-2,4-diamine,
6-(5-phenyl-2-thienyl)-1,3,5-triazine-2,4-diamine,
30 *N,N'*-[6-(4-phenylcyclohexyl)-1,3,5-triazin-2,4-diyl]bis[acetamide],
N-[4-amino-6-(4-phenylcyclohexyl)-1,3,5-triazin-2-yl]acetamide,
6-(4-phenyl-1-naphthalenyl)-1,3,5-triazine-2,4-diamine,
6-[4-(phenylthio)phenyl]-1,3,5-triazine-2,4-diamine,
6-(2-quinolinyl)-1,3,5-triazine-2,4-diamine,
35 6-(3-quinolinyl)-1,3,5-triazine-2,4-diamine,
6-(benzo[b]thien-2-ylmethyl)-1,3,5-triazine-2,4-diamine,
6-(2,2-dimethyl-2H-1-benzopyran-6-yl)-1,3,5-triazine-2,4-diamine,

6-(1-isoquinoliny)-1,3,5-triazine-2,4-diamine
(6-(2,3-dihydro-1,4-benzodioxin-2-yl)-1,3,5-triazine-2,4-diamine,
6-(tricyclo[3.3.1.1^{3,7}]decan-1-yl)-1,3,5-triazine-2,4-diamine,
(+/-)-4-(4,6-diamino-1,3,5-triazine-2-yl)- α -phenylbenzenemethanol,
5 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-1,3,5-triazine-2,4-diamine,
6-(1-azabicyclo[2.2.2]octan-4-yl)-1,3,5-triazine-2,4-diamine,
6-[4-(phenylsulfinyl)phenyl]1,3,5-triazine-2,4-diamine,
6-[4-(phenylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine,
[4-(4,6-diamino-1,3,5-triazine-2-yl)phenyl]phenylmethanone, oxime,
10 6-pyrazinyl-1,3,5-triazine-2,4-diamine,
2,4-diamino-6-[(4-phenylethenyl)phenyl]-1,3,5-triazine,
2,4-diamino-6-[(4-(2-nitrophenyl)ethenyl)phenyl]-1,3,5-triazine,
6-[1,1'-biphenyl]-4-yl-*N,N'*-dimethyl-1,3,5-triazine-2,4-diamine,
6-[1,1'-biphenyl]-4-yl-*N*-methyl-1,3,5-triazine-2,4-diamine,
15 6-(bicyclo[2.2.1]hept-2-yl)-1,3,5-triazine-2,4-diamine,
6-[1,1'-biphenyl]-4-yl-*N,N'*-diethyl-1,3,5-triazine-2,4-diamine,
6-(2'-nitro[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
6-(6-methyl-3-pyridinyl)-1,3,5-triazine-2,4-diamine,
6-(6-chloro-3-pyridinyl)-1,3,5-triazine-2,4-diamine,
20 6-(5-bromo-3-pyridinyl)-1,3,5-triazine-2,4-diamine,
6-(2,3-dihydro-2,2,3,3-tetrafluoro-1,4-benzodioxin-6-yl)-1,3,5-triazine-2,4-diamine,
6-[4-[(4-chlorophenyl)methoxy]phenyl]-1,3,5-triazine-2,4-diamine,
6-[4-(1-piperidinylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine,
6-(1-benzoyl-4-piperidinyl)-1,3,5-triazine-2,4-diamine,
25 6-[1-(phenylmethyl)-4-piperidinyl]-1,3,5-triazine-2,4-diamine,
N,N'-diacetyl-6-[4-(phenylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine,
N-acetyl-6-[4-(phenylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine, and
6-(2-piperidin-1-ylphenyl)-1,3,5-triazine-2,4-diamine.

30 Detailed Description of The Invention

Definition of Terms

The term "alkanoyl" as used herein represents an alkyl group of 1-20 carbon atoms attached to the parent molecular group through a carbonyl group.

35 The term "alkoxy" as used herein represents an alkyl group of 1-20 carbon atoms attached to the parent molecular group through an oxygen atom.

The term "alkyl" as used herein represents a monovalent group of 1-20 carbon atoms derived from a straight or branched chain saturated hydrocarbon. The alkyl groups of this invention may be substituted with 1-3 substituents independently selected from aryl or heterocycle.

5 The term "alkylene" as used herein represents a saturated divalent group of 1-20 carbon atoms derived from a straight or branched chain saturated hydrocarbon. The alkylene groups of this invention may be optionally substituted with oxo, thioxo, (=N-O-R₆), or -OR₆.

10 The term "alkenylene" as used herein represents an unsaturated divalent group of 2-20 carbon atoms derived from a straight or branched chain alkene.

The term "alkynylene" as used herein represents an unsaturated divalent group of 2-20 carbon atoms derived from a straight or branched chain alkyne.

The term "amino" as used herein represents -NH₂.

15 The term "aryl" as used herein represents a mono- or bicyclic carbocyclic ring system derived from one or two aromatic rings. The aryl groups of this invention may be optionally substituted with 1-4 substituents independently selected from alkoxy, alkyl, amino, aryl, azido, cyano, halo, haloalkyl, heterocycle, or nitro.

The term "arylalkyl" as used herein represents an aryl group attached to the parent molecular group through an alkyl group.

20 The term "azido" as used herein represents -N₃.

The term "cyano" as used herein represents -CN.

25 The term "cycloalkyl" as used herein represents a saturated monovalent group of 3-10 carbon atoms derived from a cyclic or bicyclic hydrocarbon. The cycloalkyl groups of this invention may be optionally substituted with 1-3 substituents independently selected from alkyl, aryl, or heterocycle.

The term "cycloalkenyl" as used herein represents an unsaturated monovalent group of 4-10 carbon atoms derived from a cyclic or bicyclic alkene. The cycloalkenyl groups of this invention may be optionally substituted with 1-3 substituents independently selected from alkyl, aryl, or heterocycle.

30 The term "halo" as used herein represents F, Cl, Br, or I.


The term "haloalkyl" as used herein represents an alkyl group to which is attached at least one halogen atom.

35 The term "heterocycle," as used herein, represents a 4-, 5-, 6-, or 7-membered ring containing one, two, or three heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The 4- and 5-membered rings have zero to two double bonds and the 6- and 7-membered rings have zero to three double bonds. These heterocycles include benzimidazolyl, benzofuranyl, benzothiazolyl, benzothienyl,


benzoxazolyl, dihydrothienyl, dihydroindolyl, dihydrofuranyl, dihydropyranyl, dithiazolyl, furyl, homopiperidinyl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolyl, isothiazolidinyl, isoquinolinyl, indolyl, isoxazolyl, isoxazolidinyl, isothiazolyl, morpholinyl, oxazolidinyl, oxazolyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, 5 pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrimidyl, quinolinyl, tetrahydrofuran, tetrahydroisoquinolyl, tetrahydroquinolyl, tetrahydrothienyl, tetrazolyl, thiadiazolyl, thiazolidinyl, thiazolyl, thienyl, thiomorpholinyl, triazolyl, oxadiazolyl, and the like.

10 Heterocycles also includes bicyclic, tricyclic, and tetracyclic groups in which any of the aforesigned heterocyclic rings is fused to one or two rings independently selected from an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring, or another monocyclic heterocyclic ring. These heterocycles include benzofuryl, benzothienyl, indolyl, isoquinolyl, quinolyl, tetrahydroquinolyl, and the like.

Heterocyclics also include compounds of the formula



15 , wherein X* is selected from -CH₂-, -CH₂O- and -O-, and Y* is selected from -C(O)- and -(C(R")₂)_v - wherein R" is hydrogen or alkyl of one to four carbon atoms and v is 1-3. These heterocycles include 1,3-benzodioxolyl, 1,4-benzodioxanyl, and the like. The heterocycles of this invention may be optionally substituted with 1-4 substituents independently selected from alkoxy, alkyl, amino, aryl, azido, cyano, halo, 20 haloalkyl, heterocycle, nitro, or R₁₀ and R₁₁ wherein R₁₀ and R₁₁ together are



wherein A and D are independently oxygen or S(O)_t and n is 2-3.

The term "(heterocycle)alkyl" as used herein represents an alkyl group substituted by a heterocycle. The (heterocycle)alkyl of this invention may be optionally substituted with aryl or heterocycle.

25 The term "hydroxy" as used herein represents -OH.

The term "nitro" as used herein represents -NO₂.

The term "oxo" as used herein represents (=O).

The term "pharmaceutically acceptable prodrugs" as used herein represents those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.

The term "prodrug," as used herein, represents compounds which are rapidly transformed in vivo to the parent compound of the above formula, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in 5 Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.

The term "spiroalkyl" as used herein represents an alkylene diradical, both ends of which are bonded to the same carbon atom of the parent group to form a spirocyclic 10 group. The spiroalkyl groups of this invention may be optionally substituted with 1-2 substituents independently selected from alkyl, aryl, or heterocycle.

The term "thioxo" as used herein represents (=S).

Asymmetric or chiral centers may exist in the compounds of the present invention. The present invention contemplates the various stereoisomers and mixtures thereof. 15 Individual stereoisomers of compounds of the present invention are prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of mixtures of enantiomeric compounds followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a racemic mixture of enantiomers, designated (+/-), to a chiral 20 auxiliary, separation of the resulting diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns. Pure enantiomers are designated herein by the symbols "R" or "S," depending on the configuration of substituents around the chiral carbon atom.

25 Geometric isomers may also exist in the compounds of the present invention. The present invention contemplates the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a carbocyclic ring. Substituents around a carbon-carbon double bond are designated as being in the Z or E configuration wherein the term 30 "Z" represents substituents on the same side of the carbon-carbon double bond and the term "E" represents substituents on opposite sides of the carbon-carbon double bond. The arrangement of substituents around a carbocyclic ring are designated as cis or trans wherein the term "cis" represents substituents on the same side of the plane of the ring and the term "trans" represents substituents on opposite sides of the plane of the ring. 35 Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated cis/trans.

Endothelial Cell Migration Assay

The endothelial cell migration assay was performed essentially as described by Polverini, P.J. et al., *Methods Enzymol*, 198: 440-450 (1991). Briefly, Human Microvascular Endothelial Cells (HMVEC) were starved overnight in DMEM (Dulbecco's Modified Eagle Medium) containing 0.1% bovine serum albumin (BSA). Cells were then harvested with trypsin and resuspended in DMEM with 0.1% BSA at a concentration of 1.5×10^6 cells/mL. Cells were added to the bottom of a 48-well modified Boyden chamber (Nucleopore Corporation, Cabin John, MD). The chamber was assembled and inverted, and cells were allowed to attach for 2 hours at 37 °C to polycarbonate chemotaxis membranes (5 µm pore size) that had been soaked in 0.1% gelatin overnight and dried. The chamber was then reinverted and basic fibroblast growth factor (bFGF) and test substances were added to the wells of the upper chamber (to a total volume of 50 µL); the apparatus was then incubated for 4 hours at 37 °C. Membranes were recovered, fixed and stained (DiffQuick, Fisher Scientific, Pittsburgh, PA) and the number of cells that had migrated to the upper chamber per 10 high power fields were counted. Background migration to DMEM + 0.1% BSA was subtracted and the data reported as the number of cells migrated per 10 high power fields (400X) or when results from multiple experiments were combined, as the percent inhibition of migration compared to a positive control. The results are shown in Table 1.

20

Table 1
Inhibitory Potencies Against bFGF Induced Human Microvascular Endothelial Cell
Migration of Representative Compounds

Example	% inhibition at (nM)
Irsogladine	53 % (600 nM)
1	20 (600)
3	100 (600)
4	62 (600)
6	95 (600)
7	100 (600)
8	30 (600)
9	29 (600)
10	29 (600)
12	36 (600)

Table 1 continued

Inhibitory Potencies Against bFGF Induced Human Microvascular Endothelial Cell
Migration of Representative Compounds

Example	% inhibition at (nM)
13	53 % (600 nM)
47	65 (600)
48	55 (600)
49	14 (600)
50	100 (600)
51	100 (600)
52	100 (600)
53	85 (600)
55	84 (600)
56	30 (600)
58	100 (600)
60	100 (600)
63	79 (500)
65	32 (200)
68	73 (500)
69	39 (500)
74	82 (500)
75	16 (500)
76	33 (500)
77	50 (500)

5

The compounds of the invention, including but not limited to those specified in the examples, possess anti-angiogenic activity. As angiogenesis inhibitors, such compounds are useful in the treatment of both primary and metastatic solid tumors and carcinomas of the breast; colon; rectum; lung; oropharynx; hypopharynx; esophagus; stomach; pancreas; liver; gallbladder; bile ducts; small intestine; urinary tract including kidney, bladder and urothelium; female genital tract including cervix, uterus, ovaries, choriocarcinoma and gestational trophoblastic disease; male genital tract including prostate, seminal vesicles, testes and germ cell tumors; endocrine glands including thyroid, adrenal, and pituitary;

10

skin including hemangiomas, melanomas, sarcomas arising from bone or soft tissues and Kaposi's sarcoma; tumors of the brain, nerves, eyes, and meninges including astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas and meningiomas; solid tumors arising from hematopoietic malignancies 5 such as leukemias and including chloromas, plasmacytomas, plaques and tumors of mycosis fungoides and cutaneous T-cell lymphoma/leukemia; lymphomas including both Hodgkin's and non-Hodgkin's lymphomas; prophylaxis of autoimmune diseases including rheumatoid, immune and degenerative arthritis; ocular diseases including diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, retrothalamic fibroplasia, 10 neovascular glaucoma, rubeosis, retinal neovascularization due to macular degeneration and hypoxia; abnormal neovascularization conditions of the eye; skin diseases including psoriasis; blood vessel diseases including hemangiomas and capillary proliferation within atherosclerotic plaques; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; wound granulation; 15 diseases characterized by excessive or abnormal stimulation of endothelial cells including intestinal adhesions, Crohn's disease, atherosclerosis, scleroderma and hypertrophic scars (i.e. keloids) and diseases which have angiogenesis as a pathologic consequence including cat scratch disease (*Rochele minalia quintosa*) and ulcers (*Helicobacter pylori*). Another use is as a birth control agent which inhibits ovulation and establishment of the placenta.

20 The compounds of the present invention may also be useful for the prevention of metastases from the tumors described above either when used alone or in combination with radiotherapy and/or other chemotherapeutic treatments conventionally administered to patients for treating cancer. For example, when used in the treatment of solid tumors, compounds of the present invention may be administered with chemotherapeutic agents 25 such as alpha interferon, COMP (cyclophosphamide, vincristine, methotrexate and prednisone), etoposide, mBACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone), PRO-MACE/MOPP (prednisone, methotrexate (w/leucovin rescue), doxorubicin, cyclophosphamide, taxol, etoposide/mechlorethamine, vincristine, prednisone and procarbazine), vincristine, 30 vinblastine, angioinhibins, TNP-470, pentosan polysulfate, platelet factor 4, angiostatin, LM-609, SU-101, CM-101, Techgalan, thalidomide, SP-PG and the like. Other chemotherapeutic agents include alkylating agents such as nitrogen mustards including mechlorethamine, melphan, chlorambucil, cyclophosphamide and ifosfamide; nitrosoureas including carmustine, lomustine, semustine and streptozocin; alkyl sulfonates including 35 busulfan; triazines including dacarbazine; ethylenimines including thiotapec and hexamethylmelamine; folic acid analogs including methotrexate; pyrimidine analogues including 5-fluorouracil, cytosine arabinoside; purine analogs including 6-mercaptopurine

and 6-thioguanine; antitumor antibiotics including actinomycin D; the anthracyclines including doxorubicin, bleomycin, mitomycin C and methramycin; hormones and hormone antagonists including tamoxifen and cortiosteroids and miscellaneous agents including cisplatin and brequinar.

5 The compounds of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. By "pharmaceutically acceptable salt" is meant those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are
10 commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well-known in the art. For example, S. M. Berge, *et al.* describe pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 1977, 66: 1 *et seq.* The salts may be prepared *in situ* during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable acid.
15 Representative acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate,
20 oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain
25 halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.
30

Basic addition salts can be prepared *in situ* during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary
35

ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine and the like. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, 5 piperidine, piperazine and the like. Preferred salts of the compounds of the invention include phosphate, tris and acetate.

Compounds of this invention may be combined with pharmaceutically acceptable sustained-release matrices, such as biodegradable polymers, to form therapeutic compositions. A sustained-release matrix, as used herein, is a matrix made of materials, 10 usually polymers, which are degradable by enzymatic or acid-base hydrolysis or by dissolution. Once inserted into the body, the matrix is acted upon by enzymes and body fluids. A sustained-release matrix is desirably chosen from biocompatible materials such as liposomes, polylactides (polylactic acid), polyglycolide (polymer of glycolic acid), polylactide co-glycolide (copolymers of lactic acid and glycolic acid) polyanhydrides, 15 poly(ortho)esters, polypeptides, hyaluronic acid, collagen, chondroitin sulfate, carboxylic acids, fatty acids, phospholipids, polysaccharides, nucleic acids, polyamino acids, amino acids such as phenylalanine, tyrosine, isoleucine, polynucleotides, polyvinyl propylene, polyvinylpyrrolidone and silicone. A preferred biodegradable matrix is a matrix of one of either polylactide, polyglycolide, or polylactide co-glycolide (co-polymers of lactic acid 20 and glycolic acid).

Compounds of this invention or combinations thereof may be combined with pharmaceutically acceptable excipients or carriers to form therapeutic compositions. A pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The 25 compositions may be administered parenterally, sublingually, intracisternally, intravaginally, intraperitoneally, rectally, buccally or topically (as by powder, ointment, drops, transdermal patch or iontophoresis device).

The term "parenteral," as used herein, refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and 30 intraarticular injection and infusion. Pharmaceutical compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols 35 (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity may be maintained, for

example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms 5 may be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption. Injectable 10 depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are 15 also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. The injectable formulations may be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use.

Topical administration includes administration to the skin, mucosa and surfaces of 20 the lung and eye. Compositions for topical administration, including those for inhalation, may be prepared as a dry powder which may be pressurized or non-pressurized. In non-pressurized powder compositions, the active ingredient in finely divided form may be used in admixture with a larger-sized pharmaceutically acceptable inert carrier comprising 25 particles having a size, for example, of up to 100 micrometers in diameter. Suitable inert carriers include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers. For topical administration to the eye, a compound of the invention is 30 delivered in a pharmaceutically acceptable ophthalmic vehicle such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye, as, for example, the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/ciliary, lens, choroid/retina and sclera. The pharmaceutically acceptable ophthalmic vehicle may, for example, be an ointment, vegetable oil or an encapsulating 35 material. Alternatively, a compound of the invention may be injected directly into the vitreous and aqueous humor.

The composition may be pressurized and contain a compressed gas such as nitrogen or a liquified gas propellant. The liquified propellant medium and indeed the

total composition is preferably such that the active ingredient does not dissolve therein to any substantial extent. The pressurized composition may also contain a surface active agent such as a liquid or solid non-ionic surface active agent or may be a solid anionic surface active agent. It is preferred to use the solid anionic surface active agent in the 5 form of a sodium salt.

Compositions for rectal or vaginal administration are preferably suppositories which may be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solids at room temperature but liquids at body temperature and therefore 10 melt in the rectum or vaginal cavity and release the active compound.

Compounds of the present invention may also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid 15 crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form may contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., 20 *Methods in Cell Biology*, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 *et seq.*, which is hereby incorporated herein by reference.

When used in the above or other treatments, a therapeutically effective amount of one of the compounds of the present invention may be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt form and with or without a 25 pharmaceutically acceptable excipient. A "therapeutically effective amount" of the compound of the invention means a sufficient amount of the compound to treat an angiogenic disease (for example, to limit tumor growth or to slow or block tumor metastasis) at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of 30 the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; 35 the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the

medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. Total daily dose of compounds of this invention to be administered locally or systemically to a human or other mammal host in single or divided doses may be in amounts, for example, from 0.01 to 200 mg/kg body weight daily and more usually 1 to 300 mg/kg body weight. If desired, the effective daily dose may be divided into multiple doses for purposes of administration. Consequently, single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.

10 It will be understood that agents which can be combined with the compound of the present invention for the inhibition, treatment or prophylaxis of angiogenic diseases are not limited to those listed above, but include, in principle, any agents useful for the treatment or prophylaxis of angiogenic diseases.

15 Preparation of Compounds of the Invention



Abbreviations

Abbreviations which have been used in the descriptions of the scheme and the examples that follow are: DMSO for dimethylsulfoxide, DME for dimethoxyethane, 20 EtOAc for ethyl acetate, and THF for tetrahydrofuran.

Synthetic Methods

The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes which illustrate the methods by which 25 the compounds of the invention may be prepared.


Scheme 1




As shown in Scheme 1, the triazine ring of the compounds of Formula I were prepared from condensation of esters with biguanide (Reaction 1) or from condensation of nitriles and cyanoguanidine (Reaction 2). Reaction 2 was performed in a polar, high boiling solvent such as 2-methoxyethanol and in the presence of a strong base such as 5 potassium hydroxide. Reaction 1 was performed in an alcohol, preferably methanol. The ester and nitrile precursors were purchased from commercial sources or prepared using known chemical transformations.

Scheme 2

10



R₁, R₂, R₃, and R₄ are H R₁, R₃, and R₄ are H; R₂ is alkanoyl



R₁, R₂, R₃, and R₄ are H R₁ and R₃ are H;
R₂ and R₄ are alkanoyl


15

As shown in Scheme 2, selective mono acylation to provide compounds of Formula I was accomplished by heating a diaminotriazine precursor with a carboxylic acid anhydride at elevated temperature, preferably 80-90 °C. Alternatively, 2,4-diacylation was accomplished by heating the diaminotriazine precursor with a carboxylic acid anhydride at higher temperatures, preferably 140-160 °C.

20

25


Scheme 3



As shown in Scheme 3, 2,4-diamino-6-bromoaryl-triazines were converted to compounds of Formula I using transition metal-catalyzed cross-coupling reactions catalyzed by palladium catalysts such as tetrakis(triphenylphosphine) palladium. Also, conversion of Example 20A to a 2,4-diamino-6-(trialkylstannyl)aryl-triazine by treatment with organotin reagents, preferably hexamethylditin, in the presence of a palladium catalyst such as tetrakis(triphenylphosphine) palladium, followed by cross-coupling with aryl bromides, provided an alternative route to compounds of Formula I. Treatment of Example 20A with ethynyltin reagents such as trimethyl(phenylethylyl)tin in the presence of palladium catalysts such as tetrakis(triphenylphosphine) palladium also provided compounds of Formula I.


15

Scheme 4




As shown in Scheme 4, compounds of Formula I were prepared by Friedel Crafts alkylation of aryl groups with a cycloalkenyl nitrile followed by elaboration of the nitrile intermediate as described in Scheme 1 (Reaction 2).

5

Scheme 5

A is -B-L-Y;
 B is optionally substituted heterocycle,
 Y is optionally substituted aryl, and
 L is a covalent bond

As shown in Scheme 5, piperidinyl aryl esters were converted to compounds of
 10 Formula I by arylation of isonipecotic acid esters with triarylbismuth reagents in the
 presence of copper (II) acylates.


Scheme 6

A is -B-L-Y;
 B is cyclobutyl,
 Y is aryl, and
 L is a covalent bond

15

As shown in Scheme 6, compounds of Formula I were prepared by condensation
 20 of bis-tosylates with malonic esters to construct cycloalkane rings, mono-decarboxylated
 at elevated temperatures, and further processed according to Scheme 1 (Reaction 1).

25

Scheme 7

5 As shown in Scheme 7, diaminotriazines bearing alkyl substituents on the amino groups can be prepared in a controlled and predictable manner by sequential displacement of chlorines from the triazine ring. The 6-aryl, heteroaryl, or cycloalkyl substituent may be introduced first by nucleophilic addition, for example as a Grignard reagent to cyanuric chloride, or after nitrogen introduction, for example by Pd-catalyzed Suzuki cross
 10 coupling with a boronic acid.

The compounds and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration of and not a limitation upon the scope of the invention.

15

Example 16-[1-(diphenylmethyl)-3-azetidinyl]-1,3,5-triazine-2,4-diamine

A solution of 1-(diphenylmethyl)-3-azetidinecarbonitrile (500 mg, 2.01 mmol), dicyandiamide (220 mg, 2.62 mmol) and KOH (34 mg, 0.604 mmol) in 2-methoxyethanol (10 mL) was heated at reflux for 4 hours, diluted with water, and cooled to room
 20 temperature. The precipitate was rinsed with water and dried under vacuum to provide the title compound.

mp 126-128 °C;

MS (DCI/NH₃) m/e 333 (M+H)⁺;

25 ¹H NMR (300 MHz, DMSO-d₆) δ 7.3 (d, 4H), 7.2 (t, 4H), 7.05 (t, 2H), 6.5-6.7 (br s, 4H), 4.35 (s, 1H), 3.2-3.3 (m, 3H), 3.1-3.15 (m, 2H);

Anal. calcd for C₁₉H₂₀N₆·0.75H₂O: C, 65.97; H, 6.26; N, 24.29. Found: C, 65.67; H, 5.65; N, 23.84.

5 Example 2

6-(1-phenyl-4-piperidinyl)-1,3,5-triazine-2,4-diamine

Example 2A

A solution of triphenylbismuth (5.02 g, 11.4 mmol), cupric acetate (1.79 g, 9.85 mmol), and ethyl isonipecotate (1.5 mL, 9.7 mmol) in dichloromethane (100 mL) was 10 stirred at room temperature for 18 hours, diluted with water, and filtered through Celite®. The organic layer was dried (MgSO₄), and concentrated. The residue was purified by flash chromatography on silica gel with 0-2% acetone/dichloromethane to provide the designated compound.

MS (DCI/NH₃) m/e 234 (M+H)⁺.

15

Example 2B

The designated compound was prepared as in Inorganic Synthesis, Volume 7, pp. 56-58 (1963).

20

Example 2C

6-(1-Phenyl-4-piperidinyl)-1,3,5-triazine-2,4-diamine

A solution of Examples 2A (0.464 g, 1.99 mmol) and 2B (0.211 g, 2.09 mmol) in methanol (4 mL) was stirred at room temperature for 16 hours. The precipitate was rinsed with methanol, dried under vacuum, and recrystallized from dioxane/ethanol to provide 25 the title compound.

mp 202-204 °C;

MS (DCI/NH₃) m/e 271 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 7.19 (t, 2H), 6.94 (d, 2H), 6.72 (t, 1H), 6.56 (br s, 4H), 4.11 (q, 2H), 3.77 (m, 2H), 2.75 (dt, 2H), 2.41 (m, 1H), 1.79 (m, 2H);

30 Anal. calcd for C₁₄H₁₈N₆·0.67H₂O: C, 59.58; H, 6.90; N, 27.78. Found: C, 59.27; H, 6.79; N, 25.51.

35 Example 3

trans-6-(4-phenylcyclohexyl)-1,3,5-triazine-2,4-diamine

Example 3A

4-phenylhexenecarbonitrile

5 A solution of cyclohexenecarbonitrile (9 mL, 80.6 mmol) and benzene (75 mL) was treated portionwise with AlCl₃ (13 g, 97 mmol) then stirred at room temperature for 2 hours. The mixture was poured onto ice and extracted with ethyl acetate. The extract was washed sequentially with water and brine, dried (MgSO₄), and concentrated. The residue was distilled at 125 °C (0.6 mm Hg) to provide the title compound.
MS (DCI/NH₃) m/e 203 (M+NH₄)⁺.

Example 3Btrans-6-(4-phenylcyclohexyl)-1,3,5-triazine-2,4-diamine

10 Example 3A was processed as in Example 1 to provide the title compound.
MS (DCI/NH₃) m/e 270 (M+H)⁺;
1H NMR (300 MHz, DMSO-d₆) δ 7.20-7.32 (m, 4H), 7.12-7.18 (m, 1H), 6.57 (br s, 4H), 2.46 (tt, 1H), 2.32 (tt, 1H), 1.80-1.93 (m, 4H), 1.41-1.66 (m, 4H);
15 Anal. calcd for C₁₅H₁₉N₅: C, 66.88; H, 7.11; N, 26.00. Found: C, 66.85; H, 7.00; N, 26.08.

Example 46-[3-(1H-pyrrol-1-yl)phenyl]-1,3,5-triazine-2,4-diamine

20 3-(1H-pyrrol-1-yl)benzonitrile was processed as in Example 1 to provide the title compound.
mp 164-170 °C;
MS (DCI/NH₃) m/e 253 (M+H)⁺;
1H NMR (300 MHz, DMSO-d₆) δ 8.35 (s, 1H), 8.15 (d, 1H), 7.7 (dd, 1H), 7.6-7.5 (m, 1H), 7.3 (t, 3H), 7.0-6.8 (br s, 4H), 6.3-6.25 (m, 2H);
25 Anal. calcd for C₁₃H₁₂N₆: C, 61.89; H, 4.79; N, 33.31. Found: C, 62.20; H, 4.56; N, 32.39.

Example 5cis/trans-6-(3-phenylcyclobutyl)-1,3,5-triazine-2,4-diamine

30 A solution of cis/trans-methyl 3-phenylcyclobutane-1-carboxylate, prepared as in J. Am. Chem. Soc. 1985, 107, 7247-7257, was processed as in Example 2C to provide the title compounds.
mp 98-102 °C;
35 1H NMR (300 MHz, DMSO-d₆) δ 7.31 (m, 4H), 7.19 (m, 1H), 6.60 (m, 4H), 3.62 (m, 0.4H), 3.43 (m, 0.4H), 3.18 (m, 0.8H), 2.88 (m, 0.8H), 2.56 (m, 1.2H), 2.38 (m, 2.4H);

Anal. calcd for $C_{13}H_{15}N_5 \cdot 0.5CH_3CO_2CH_2CH_3$: C, 63.14; H, 6.71; N, 24.54. Found: C, 62.75; H, 6.73; N, 24.48.

Example 6

6-[1,1'-biphenyl]-2-yl-1,3,5-triazine-2,4-diamine

[1,1'-biphenyl]-2-carbonitrile was processed as in Example 1 to provide the title compound.

MS (DCI/NH₃) m/e 264 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 7.63-7.2 (m, 5H), 7.37-7.27 (m, 4H), 6.6 (br s, 4H);

Anal. calcd for C₁₅H₁₃N₅: C, 68.42; H, 4.97; N, 26.59. Found: C, 67.85; H, 4.94; N, 26.50.

Example 7

6-(4'-nitro[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine

4'-Nitro-[1,1'-biphenyl]-4-carbonitrile was processed as in Example 1 to provide the title compound.

mp >250 °C;

MS (DCI/NH₃) m/e 309 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.5-8.4 (m, 4H), 8.1 (d, 2H), 7.95 (d, 2H), 6.85 (br s,

4H);

Anal. calcd for C₁₅H₁₂N₆O₂: C, 58.43; H, 3.92; N, 27.42. Found: C, 58.46; H, 3.76; N, 27.12.

Example 8

trans-6-[4-(4-pentylcyclohexyl)phenyl]-1,3,5-triazine-2,4-diamine

4-(Trans-4-pentylcyclohexyl)benzonitrile was processed as in Example 1 to provide the title compound.

mp >250 °C;

MS (DCI/NH₃) m/e 340 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.2 (d, 2H), 7.3 (d, 2H), 6.75 (bs, 4H), 1.85 (d, 4H), 1.55-1.4 (m, 2H), 1.37-1.2 (m, 10H), 1.1-1.05 (m, 2H), .85 (t, 3H);

Anal. calcd for C₂₀H₂₉N₅: C, 70.76; H, 8.61; N, 20.62. Found: C, 70.71; H, 8.73; N, 20.67.

Example 9

6-(4-phenoxyphenyl)-1,3,5-triazine-2,4-diamine

4-Phenoxybenzonitrile was processed as in Example 1 to provide the title compound.

mp 198-200 °C;

MS (DCI/NH₃) m/e 280 (M+H)⁺;

5 ¹H NMR (300 MHz, DMSO-d₆) δ 8.3-8.2 (m, 2H), 7.5-7.4 (m, 2H), 7.2 (t, 1H), 7.17-7.0 (m, 4H), 6.9-6.65 (br s, 4H);
Anal. calcd for C₁₅H₁₃N₅O: C, 64.51; H, 4.69; N, 25.07. Found: C, 63.84; H, 4.67; N, 24.90.

10

Example 10

N-cyclohexyl-N'-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]urea

Example 10A

4-Aminobenzonitrile was processed as in Example 1 to provide the designated compound.

MS (DCI/NH₃) m/e 203 (M+H)⁺.

Example 10B

N-cyclohexyl-N'-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]urea

A mixture of Example 10A (1.0 g; 4.9 mmol), cyclohexylisocyanate (610 mg, 4.9 mmol), and triethylamine (0.68 mL, 4.9 mmol) in dioxane was stirred overnight at room temperature. The precipitate was washed with water and dried under vacuum to provide the title compound.

MS (DCI/NH₃) m/e 328 (M+H)⁺;

1¹H NMR (300 MHz, DMSO-d₆) δ 8.4 (s, 1H), 8.23 (t, 1H), 8.8-8.75 (m, 1H), 7.55-7.45 (m, 1H), 7.25-7.2 (t, 1H), 7.0-6.8 (br s, 4H), 6.0 (d, 1H), 3.55-3.4 (m, 1H), 1.9-1.8 (m, 2H), 1.7-1.6 (m, 2H), 1.59-1.5 (m, 1H), 1.2-0.5 (m, 5H);
Anal. calcd for C₁₅H₂₁N₇O: C, 58.70; H, 6.47; N, 29.95. Found: C, 58.49; H, 6.59; N, 29.49.

30

Example 11

(4,6-diamino-1,3,5-triazine-2-yl)phenylmethenone

4-Cyanobenzophenone was processed as in Example 1 to provide the title compound.

mp >250 °C;

35 ¹H NMR (300 MHz, DMSO-d₆) δ 8.4 (d, 2H), 7.9 (d, 2H), 7.8 (m, 2H), 7.7 (m, 1H), 7.6 (t, 2H), 6.9 (br s, 4H);

MS (DCI/NH₃) m/e 292 (M+H)⁺;

Anal. calcd for C₁₆H₁₃N₅O: C, 65.97; H, 4.50; N, 24.04. Found: C, 65.74; H, 4.32; N, 23.93.

Example 12

N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]-N'-phenyl urea

Example 10A was processed as in Example 10B but substituting phenylisocyanate for cyclohexylisocyanate to provide the title compound.

¹H NMR (300 MHz, DMSO-d₆) δ 8.8 (s, 1H), 8.65 (s, 1H), 8.35 (t, 1H), 7.9 (d, 1H), 7.6-7.5 (m, 1H), 7.49-7.44 (m, 2H), 7.35 (t, 1H), 7.29 (t, 2H), 7.0 (t, 1H), 6.8-6.7 (br s, 4H);

Anal. calcd for C₁₆H₁₅N₇O: C, 59.80; H, 4.70; N, 30.51. Found: C, 59.61; H, 4.72; N, 29.91.

Example 13

6-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1,3,5-triazine-2,4-diamine

A mixture of 2,4-diamino-6-chloro-1,3,5-triazine (2 g, 14 mmol), 1,4-dioxa-8-azaspiro[4.5]decane (3 g, 21 mmol), and KOH (100 mg, 1.8 mmol) in dioxane (10 mL) and ethanol (40 mL) was heated at reflux overnight, diluted with water, and filtered. The precipitate was rinsed with water and dried under vacuum to provide the title compound. mp 209-211 °C;

MS (DCI/NH₃) m/e 253 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 6.14 (br s, 4H), 3.90 (s, 4H), 3.75-3.68 (m, 4H), 1.58-1.51 (m, 4H);

Anal. calcd for C₁₀H₁₆N₆O₂: C, 47.61; H, 6.39; N, 33.31. Found: C, 47.45; H, 6.34; N, 33.24.

25

Example 14

6-(4'-pentyl[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine

4'-Pentyl[1,1'-biphenyl]-4-carbonitrile was processed as in Example 1 to provide the title compound.

mp 242-244 °C;

MS (DCI/NH₃) m/e 334 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.3 (d, 2H), 8.75 (d, 2H), 8.65 (d, 2H), 7.3 (d, 2H), 6.75-6.82 (br s, 4H), 2.6 (t, 2H), 1.6-1.7 (m, 2H), 1.3-1.4 (m, 4H), 0.95 (t, 3H);

Anal. calcd for C₂₀H₂₃N₅·0.25H₂O: C, 71.61; H, 7.09; N, 20.03. Found: C, 71.80; H, 7.00; N, 20.45.

Example 156-[4'-pentyloxy[1,1'-biphenyl]-4-yl]-1,3,5-triazine-2,4-diamine

4'-(Pentyloxy)[1,1'-biphenyl]-4-carbonitrile was processed as in Example 1 to provide the title compound.

5 mp 246-249 °C;
 MS (DCI/NH₃) m/e 350 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 8.3 (d, 2H), 7.75-7.65 (m, 4H), 7.07 (d, 2H), 6.85-6.7 (br s, 4H), 4.05 (t, 2H), 1.8-1.7 (m, 2H), 1.5-1.3 (m, 4H), 0.9 (t, 3H);
 Anal. calcd for C₂₀H₂₃N₅O: C, 68.75; H, 6.63; N, 20.04. Found: C, 68.64; H, 6.77; N, 10 19.94.

Example 166-(6-methoxy-2-benzothiazolyl)-1,3,5-triazine-2,4-diamine

6-Methoxy-2-benzothiazolecarbonitrile was processed as in Example 1 to provide

15 the title compound.
 mp >250 °C;
 MS (DCI/NH₃) m/e 275 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 7.98 (d, 1H), 7.71 (d, 1H), 7.17 (dd, 1H), 7.16 (br s, 2H), 6.95 (br s, 2H), 3.85 (s, 3H);
 20 Anal. calcd for C₁₁H₁₀N₆OS: C, 48.17; H, 3.67; N, 30.64. Found: C, 48.07; H, 3.75; N, 30.72.

Example 176-(4'-amino[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine

4'-Amino[1,1'-biphenyl]-4-carbonitrile was processed as in Example 1 to provide the title compound.

mp >250 °C;
 MS (DCI/NH₃) m/e 279 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 8.25 (d, 2H), 7.65 (d, 2H), 7.45 (d, 2H), 6.8-6.6 (m, 30 6H), 5.3 (s, 2H);
 Anal. calcd for C₁₅H₁₄N₆: C, 64.73; H, 5.07; N, 30.20. Found: C, 64.34; H, 5.18; N, 29.91.

Example 186-[4-(5-oxazolyl)phenyl]-1,3,5-triazine-2,4-diamine

4-(5-Oxazolyl)benzonitrile was processed as in Example 1 to provide the title compound.

MS (DCI/NH₃) m/e 255 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 8.55 (s, 1H), 8.37 (d, 2H), 7.9-7.8 (t, 3H), 6.9-6.7 (br s, 4H);
Anal. calcd for C₁₂H₁₀N₆O: C, 56.69; H, 3.96; N, 33.05. Found: C, 56.40; H, 4.02; N, 5 33.11.

Example 19

6-[4-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]-1,3,5-triazine-2,4-diamine

4-[[5-(Trifluoromethyl)-2-pyridinyl]oxy]benzonitrile was processed as in Example 10 1 to provide the title compound.
MS (DCI/NH₃) m/e 349 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 8.6 (s, 1H), 8.6-8.5 (m, 3H), 7.4-7.3 (m, 3H), 6.9-6.7 (br s, 4H);
Anal. calcd for C₁₅H₁₁F₃N₆O: C, 51.73; H, 3.18; N, 24.13. Found: C, 51.67; H, 3.20; N, 15 23.83.

Example 20

4'-(4,6-diamino-1,3,5-triazine-2-yl)[1,1'-biphenyl]-4-carbonitrile

Example 20A

4-Bromobenzonitrile was processed as in Example 1 to provide the designated compound.

MS (DCI/NH₃) m/e 267 (M+H)⁺.

Example 20B

25 A solution of Example 20A (0.76 g, 2.9 mmol) and tetrakis(triphenylphosphine) palladium (0.17 g, 0.15 mmol) in dry, degassed dimethylacetamide (45 mL) was heated to 100 °C, treated with hexamethylditin (1.0 g, 3.1 mmol), heated at 100 °C for 3 hours, treated with ethyl acetate, washed sequentially with 1M NaOH and brine, dried (MgSO₄), and concentrated to provide the designated compound.

30 MS (DCI/NH₃) m/e 352 (M+H)⁺.

Example 20C

4'-(4,6-diamino-1,3,5-triazine-2-yl)[1,1'-biphenyl]-4-carbonitrile

35 A solution of Example 20B (0.95 g, 2.7 mmol), 4-bromobenzonitrile (0.55 g, 3.0 mmol) and tetrakis(triphenylphosphine) palladium (0.20 g, 0.17 mmol) in dry, degassed dimethylacetamide (45 mL) was heated at 100 °C for 3 hours, cooled to room

temperature, treated with ethyl acetate, washed sequentially with 1M NaOH and brine, dried (MgSO₄), and concentrated. The residue was recrystallized from dioxane/ethanol to provide the title compound.

mp >260 °C;

5 MS (DCI/NH₃) m/e 289 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.36 (d, 2H), 7.96 (s, 4H), 7.88 (d, 2H), 6.81 (br s, 4H);

Anal. calcd for C₁₆H₁₂N₆·0.75H₂O: C, 63.67; H, 4.51; N, 27.84. Found: C, 64.06; H, 4.38; N, 27.17.

10

Example 21

6-(4'-methoxy[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine

A solution of Example 20A (0.749 g, 2.8 mmol) and tetrakis(triphenylphosphine) palladium (0.15 g, 0.13 mmol) in dry, degassed dimethylacetamide (45 mL) was heated to 100 °C, treated sequentially with 4-methoxyphenyl boronic acid (0.648 g, 4.3 mmol) in absolute ethanol (15 mL) and saturated NaHCO₃ (30 mL), heated at 100 °C for 3 hours, cooled to room temperature, treated with ethyl acetate, washed with brine, dried (MgSO₄), and concentrated. The residue was recrystallized from dioxane/ethanol to provide the title compound.

20 mp >260 °C;

MS (DCI/NH₃) m/e 294 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.31 (d, 2H), 7.72 (t, 4H), 7.03 (d, 2H), 6.86 (br s, 4H), 3.81 (s, 3H);

Anal. calcd for C₁₆H₁₅N₅O·0.33H₂O: C, 64.21; H, 5.27; N, 23.40. Found: C, 64.26; H, 5.35; N, 23.43.

Example 22

6-(4'-fluoro[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine

Example 20A and 4-fluorophenyl boronic acid were processed as in Example 24 to provide the title compound.

30 mp >260 °C;

MS (DCI/NH₃) m/e 282 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.32 (d, 2H), 7.77 (m, 4H), 7.32 (t, 2H), 6.75 (br s, 4H);

35 Anal. calcd for C₁₅H₁₂FN₅·0.25H₂O: C, 63.04; H, 4.41; N, 24.50. Found: C, 63.41; H, 4.49; N, 24.17.

Example 23N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]benzenesulfonamide

5 A solution of Example 10A, (575 mg, 2.8 mmol) and benzenesulfonyl chloride (554 mg, 3.1 mmol) in pyridine (5 mL) was heated at reflux for 4 hours, stirred overnight at room temperature, treated with water and extracted with ethyl acetate. The extract was washed with water and brine, dried (MgSO_4), and concentrated. The residue was recrystallized from ethanol to provide the title compound.

mp 197-199 °C;

MS (DCI/ NH_3) m/e 343 ($\text{M}+\text{H})^+$;

10 ^1H NMR (300 MHz, DMSO-d_6) δ 10.20 (br s, 1H), 8.03-8.01 (m, 1H), 7.94-7.91 (m, 1H), 7.80-7.78 (m, 2H), 7.60-7.50 (m, 3H), 7.34-7.25 (m, 1H), 7.22-7.19 (m, 1H);
 Anal. calcd for $\text{C}_{15}\text{H}_{14}\text{N}_6\text{O}_2\text{S}\cdot\text{C}_2\text{H}_5\text{OH}$: C, 52.56; H, 5.18; N, 21.63. Found: C, 52.47; H, 5.24; N, 21.54.

15

Example 246-[1-([1,1'-biphenyl]-4-yl)-4-piperidinyl]-1,3,5-triazine-2,4-diamineExample 24A

20 A mixture of 4-bromobiphenyl (19.16 g, 82 mmol) in THF (820 mL) at -78 °C was treated with tert-butyllithium (100 mL of a 1.7 M solution in pentane, 170 mmol), stirred for 8 minutes, treated with bismuth trichloride (8.62 g, 27.4 mmol) in THF (100 mL), stirred an additional 3 hours, treated with saturated aqueous NH_4Cl , and extracted with ethyl acetate. The extract was washed with water and brine, dried over (MgSO_4) and concentrated. The residue was dried in a vacuum oven to provide the designated compound.

25 ^{13}C NMR (300 MHz, CDCl_3) δ 153.83, 141.04, 140.69, 138.07, 129.21, 128.75, 127.33, 127.07.

Example 24B6-[1-([1,1'-biphenyl]-4-yl)-4-piperidinyl]-1,3,5-triazine-2,4-diamine

30 Example 24A and ethyl isonipecotate were processed as in Examples 2A and 2C to provide the title compound.

mp >260 °C;

MS (DCI/ NH_3) m/e 347 ($\text{M}+\text{H})^+$;

35 ^1H NMR (300 MHz, DMSO-d_6) δ 7.58 (m, 2H), 7.47 (d, 2H), 7.39 (m, 2H), 7.23 (m, 1H), 6.97 (d, 2H), 6.59 (br s, 4H), 3.61 (m, 1H), 1.78 (m, 4H), 1.58 (m, 4H).

Example 25N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]-2-naphthalenesulfonamide

6-(4-Aminophenyl)-1,3,5-triazine-2,4-diamine was processed as in Example 23 but substituting 2-naphthalenesulfonyl chloride for benzenesulfonyl chloride to provide
5 the title compound.

mp 230-233 °C;

MS (DCI/NH₃) m/e 393 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 10.55 (s, 1H), 8.5 (s, 1H), 8.2-8.05 (m, 3H), 8.0 (d, 1H), 7.9-7.85 (m, 1H), 7.8-7.75 (m, 1H), 7.74-7.6 (m, 2H), 7.3-7.2 (m, 2H), 6.9-6.65 (br 10 s, 4H);

Anal. calcd for C₁₉H₁₆N₆O₂S·1.5 C₄H₈O₂: C, 57.23; H, 5.37; N, 16.02. Found: C, 57.11; H, 5.33; N, 16.28.

Example 262,5-dichloro-N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]benzenesulfonamide

Example 10A was processed as in Example 23 but substituting 2,5-dichlorobenzenesulfonyl chloride for benzenesulfonyl chloride to provide the title compound.

mp 230-233 °C;

MS (DCI/NH₃) m/e 411 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 10.5 (s, 1H), 8.05 (m, 3H), 7.75-7.7 (m, 2H), 7.35 (t, 1H), 7.25-7.2 (m, 1H), 6.8-6.7 (br s, 4H);

Anal. calcd for C₁₅H₁₂Cl₂N₆O₂S·0.5CH₃CH₂OH C, 44.24; H, 3.48; N, 19.35. Found: C, 44.43; H, 3.26; N, 19.44.

25

Example 276-(1-phenylcyclohexyl)-1,3,5-triazine-2,4-diamine

1-Phenylcyclohexanecarbonitrile was processed as in Example 1 to provide the title compound.

30 mp 153-155 °C;

MS (DCI/NH₃) m/e 270 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 7.4-7.3 (m, 2H), 7.15 (t, 2H), 7.2-7.1 (m, 1H), 6.6-6.5 (br s, 4H), 2.7-2.6 (m, 2H), 1.75-1.6 (m, 2H), 1.6-1.2 (m, 6H);

Anal. calcd for C₁₅H₁₉N₅: C, 66.89; H, 7.11; N, 26.00. Found: C, 66.94; H, 7.20; N,

35 26.04.

Example 28

6-[1-(4-methoxyphenyl)-4-piperidinyl]-1,3,5-triazine-2,4-diamine

Tris(4'-methoxy[1,1'-biphenyl]bismuth, prepared as in Example 24A, and ethyl isonipecotate were processed as in Examples 2A and 2C to provide the title compound. mp 204-205 °C;

5 MS (DCI/NH₃) m/e 301 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 6.92 (d, 2H), 6.81 (d, 2H), 6.58 (m, 4H), 3.59 (m, 2H), 2.62 (m, 2H), 2.35 (m, 1H), 1.82 (m, 4H).

Example 296-[2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]-1,3,5-triazine-2,4-diamine

Ethyl 2-[4-(trifluoromethyl)phenyl]thiazole-4-carboxylate and Example 2B were processed as in Example 2C to provide the title compound.

mp >260 °C;

10 MS (DCI/NH₃) m/e 339 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 8.42 (s, 1H), 8.19 (d, 2H), 7.91 (d, 2H), 6.82 (br s, 4H);
Anal. calcd for C₁₃H₉F₃N₆S: C, 46.15; H, 2.68; N, 24.84. Found: C, 45.85; H, 2.64; N, 24.44.

Example 306-[1-(4-methoxyphenyl)cyclohexyl]-1,3,5-triazine-2,4-diamine

1-(4-Methoxyphenyl)cyclohexanecarbonitrile was processed as in Example 1 to provide the title compound.

mp 159-163 °C;

15 MS (DCI/NH₃) m/e 300 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 7.15 (d, 2H), 6.8 (d, 2H), 6.6 (br s, 4H), 3.7 (s, 3H), 2.7-2.6 (m, 2H), 1.7-1.6 (m, 2H), 1.6-1.2 (m, 6H);
Anal. calcd for C₁₆H₂₁N₅O: C, 64.19; H, 7.07; N, 23.39. Found: C, 64.13; H, 7.07; N, 23.25.

30

Example 316-[4-(2-thienyl)phenyl]-1,3,5-triazine-2,4-diamine

A solution of Example 20A (500 mg, 1.9 mmol) and 2-tri-n-butyltinthiophene (840 mg, 2.2 mmol) in dry, degassed dimethylacetamide (15 mL) was treated with 35 tetrakis(triphenylphosphine) palladium (115 mg, 0.1 mmol), heated at 100 °C for 3 hours, cooled, treated with 1N NaOH, and extracted with ethyl acetate. The extract was washed

with brine, dried (MgSO_4), and concentrated. The residue was recrystallized from ethanol/dioxane to provide the title compound.

mp >260;

MS (DCI/ NH_3) m/e 270 ($\text{M}+\text{H}$) $^+$;

5 ^1H NMR (300 MHz, DMSO-d_6) δ 8.31-8.24 (m, 2H), 7.8-7.72 (m, 2H), 7.62-7.59 (m, 2H), 7.2-7.16 (m, 1H), 6.92 (br s, 4H);
Anal. calcd for $\text{C}_{13}\text{H}_{11}\text{N}_5\text{S}$: C, 57.97; H, 4.11; N, 26.00. Found: C, 57.91; H, 4.06; N, 25.83.

10

Example 32

6-[4-(phenylethynyl)phenyl]-1,3,5-triazine-2,4-diamine

Example 32A

4-Bromobenzonitrile and trimethyl(phenylethynyl)tin were processed as in
15 Example 31 to provide the designated compound.
MS (DCI/ NH_3) m/e 221 ($\text{M}+\text{NH}_4$) $^+$.

20

Example 32B

6-[4-(phenylethynyl)phenyl]-1,3,5-triazine-2,4-diamine

4-(Phenylethynyl)benzonitrile was processed as in Example 1 to provide the title
compound.
mp 248-249 °C;
MS (DCI/ NH_3) m/e 289 ($\text{M}+\text{H}$) $^+$;
1 ^1H NMR (300 MHz, DMSO-d_6) δ 8.30 (d, 2H), 7.67 (d, 2H), 7.61-7.58 (m, 2H), 7.5-7.43
25 (m, 3H), 6.82 (br s, 4H);
Anal. calcd for $\text{C}_{17}\text{H}_{13}\text{N}_5$: C, 71.06; H, 4.56; N, 24.37. Found: C, 70.79; H, 4.73; N, 24.08.

30

Example 33

N,N-(6-[1,1'-biphenyl]-4-yl-1,3,5-triazin-2,4-diyl)bis[acetamide]

Example 33A

4-Phenylbenzonitrile was processed as in Example 1 to provide the designated
compound.
35 MS (DCI/ NH_3) m/e 264 ($\text{M}+\text{H}$) $^+$.

Example 33BN,N-(6-[1,1'-biphenyl]-4-yl-1,3,5-triazin-2,4-diy)bis[acetamide]

A solution of Example 33A (0.26g, 0.99 mmol) in acetic anhydride (10 mL) was refluxed for 20 hours and cooled to room temperature. The precipitate was rinsed with 5 saturated NaHCO₃, and dried under vacuum to provide the title compound.

mp >260 °C;

MS (DCI/NH₃) m/e 348 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 10.79 (s, 2H), 8.43 (d, 2H), 7.91 (d, 2H), 7.79 (d, 2H), 7.52 (m, 2H), 7.41 (m, 1H), 2.41 (s, 6H);

10 Anal. calcd for C₁₉H₁₇N₅O₂: C, 65.70; H, 4.93; N, 20.16. Found: C, 65.63; H, 4.84; N, 20.18.

Example 34N-(4-amino-6-[1,1'-biphenyl]-4-yl-1,3,5-triazin-2-yl)acetamide

15 A solution of Example 33A (0.38g, 1.4 mmol) in acetic anhydride (4 mL) was heated at 80 °C for 20 hours, treated with ethyl acetate and cooled to room temperature. The precipitate was collected by vacuum filtration, rinsed with aqueous sodium carbonate, and dried under vacuum to yield the title compound.

mp >260 °C;

20 MS (DCI/NH₃) m/e 306 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 10.22 (s, 1H), 8.39 (d, 2H), 7.83 (d, 2H), 7.77 (d, 2H), 7.53 (m, 3H), 7.41 (m, 2H), 2.36 (s, 3H);

Anal. calcd for C₁₇H₁₅N₅O·0.2CH₃CO₂H: C, 65.86; H, 5.02; N, 22.07. Found: C, 65.82; H, 4.97; N, 22.37.

25

Example 35N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]-1-naphthalenesulfonamide

Example 10A was processed as in Example 23 but substituting 1-

naphthalenesulfonyl chloride for benzenesulfonyl chloride to provide the title compound.

30 mp >250 °C;

MS (DCI/NH₃) m/e 393 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 10.8 (s, 1H), 8.8 (d, 1H), 8.3 (d, 1H), 8.2 (d, 1H), 8.1 (d, 1H), 8.0 (s, 1H), 7.83-7.6 (m, 4H), 7.2 (t, 1H), 7.15-7.1 (m, 1H), 6.83-6.7 (m, 4H);

Anal. calcd for C₁₉H₁₆N₆O₂S·H₂O: C, 55.59; H, 4.42; N, 20.47. Found: C, 55.57; H, 35 4.42; N, 20.52.

Example 36

6-(4'-azido[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamineExample 36A

A solution of 4'-amino[1,1'-biphenyl]-4-carbonitrile (0.490 g, 2.53 mmol) in 5 trifluoroacetic acid (12.5 mL) was treated sequentially with sodium nitrite (0.338 g, 4.90 mmol) and sodium azide (0.33 g, 5.1 mmol), stirred at room temperature for 10 minutes, treated with water and extracted with ethyl acetate. The extract was dried (MgSO_4), concentrated to provide the designated compound.

MS (DCI/ NH_3) m/e 238 ($\text{M}+\text{NH}_4$)⁺.

10

Example 36B6-(4'-azido-[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine

Example 36A was processed as in Example 1 to provide the title compound.

mp 230 °C (decomposes);

15 MS (DCI/ NH_3) m/e 305 ($\text{M}+\text{H}$)⁺;

^1H NMR (300 MHz, DMSO-d_6) δ 8.32 (d, 2H), 7.79 (m, 4H), 7.24 (d, 2H), 6.74 (bds, 4H);

Anal. calcd for $\text{C}_{15}\text{H}_{12}\text{N}_8 \cdot 0.33\text{H}_2\text{O}$: C, 58.07; H, 4.11; N, 36.12. Found: C, 58.15; H, 3.84; N, 33.09.

20

Example 376-[4-(4-morpholinylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamineExample 37A

A solution of 4-cyanobenzenesulfonyl chloride (600 mg, 2.98 mmol), morpholine (300 mg, 3.44 mmol), and pyridine (350 μL , 342 mg, 4.33 mmol) in dichloromethane (10 ml) was stirred overnight at room temperature, treated with saturated NH_4Cl and extracted with ethyl acetate. The extract was washed with water and brine, dried (MgSO_4) and concentrated to provide the designated compound.

30 MS (DCI/ NH_3) m/e 270 ($\text{M}+\text{NH}_4$)⁺.

Example 37B4-(2,4-diamino-1,3,5-triazin-2-yl)-N-(4-morpholinyl)benzenesulfonamide

Example 37A was processed as in Example 1 to provide the title compound.

35 mp >260 °C;

MS (DCI/ NH_3) m/e 337 ($\text{M}+\text{H}$)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.46 (d, 2H), 7.83 (d, 2H), 6.91 (br s, 4H), 3.65-3.60 (m, 4H), 2.94-2.88 (m, 4H);

Anal. calcd for C₁₃H₁₆N₆O₃S: C, 46.42; H, 4.79; N, 24.98. Found: C, 46.21; H, 4.69; N, 25.24.

5

Example 38

6-[4-(2-furanyl)phenyl]-1,3,5-triazine-2,4-diamine

6-(4-Bromophenyl)-1,3,5-triazine-2,4-diamine was processed as in Example 31 but substituting 2-tri-n-butyltinfurran for 2-tri-n-butyltinthiophene to provide the title compound.

MS (DCI/NH₃) m/e 254 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.3 (d, 2H), 7.8 (d, 3H), 7.05 (d, 1H), 6.8-6.7 (br s, 4H), 6.65-6.6 (m, 1H);

Anal. calcd for C₁₃H₁₁N₅O: C, 60.30; H, 5.57; N, 24.30. Found: C, 59.83; H, 5.44; N, 24.86.

Example 39

N,N-[6-(4-phenoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[acetamide]

Example 9 was processed as in Example 33B to provide the title compound.

mp 243-245 °C;

MS (DCI/NH₃) m/e 364 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 10.74 (s, 2H), 8.38 (d, 2H), 7.47 (t, 2H), 7.24 (t, 1H), 7.14 (dd, 4H), 2.38 (s, 6H);

Anal. calcd for C₁₉H₁₇N₅O₃: C, 62.80; H, 4.72; N, 19.27. Found: C, 62.56; H, 4.82; N, 19.40.

Example 40

N-[4-amino-6-(4-phenoxyphenyl)-1,3,5-triazin-2-yl]acetamide

Example 9 was processed as in Example 34 to provide the title compound.

mp >260 °C;

MS (DCI/NH₃) m/e 322 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 10.21 (s, 1H), 8.32 (d, 2H), 7.46 (t, 2H), 7.37 (bds, 2H), 7.13 (d, 2H), 7.08 (d, 2H), 2.32 (s, 3H);

Anal. calcd for C₁₇H₁₅N₅O₂: C, 63.54; H, 4.71; N, 21.79. Found: C, 63.25; H, 4.79; N, 21.84.

Example 416-(5-phenyl-2-furanyl)-1,3,5-triazine-2,4-diamineExample 41A

5 Methyl 5-bromo-2-furoate, phenylboronic acid, and tetrakis(triphenylphosphine) palladium were processed as in Example 21 to provide the designated compound. MS (DCI/NH₃) m/e 203 (M+H)⁺.

Example 41B6-(5-phenyl-2-furanyl)-1,3,5-triazine-2,4-diamine

10 Examples 41A and 2B were processed as in Example 2C to provide the title compound.

mp >260 °C;

MS (DCI/NH₃) m/e 254 (M+H)⁺;

15 ¹H NMR (300 MHz, DMSO-d₆) δ 7.80 (d, 2H), 7.52-7.44 (m, 2H), 7.41-7.37 (m, 1H), 7.23 (dd, 1H), 7.16 (dd, 1H), 6.78 (br s, 4H);
Anal. calcd for C₁₃H₁₁N₅O: C, 61.65; H, 4.37; N, 27.65. Found: C, 61.33; H, 4.37; N, 27.42.

20

Example 426-(5-phenyl-2-thienyl)-1,3,5-triazine-2,4-diamine

Methyl 5-phenylthiophene-2-carboxylate was processed as in Examples 41A and 41B to provide the title compound.

mp >250 °C;

25 MS (DCI/NH₃) m/e 270 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 7.80 (d, 1H), 7.71-7.76 (m, 2H), 7.56 (d, 1H), 7.31-7.49 (m, 3H), 6.78 (bds, 4H);

Anal. calcd for C₁₃H₁₁N₅S·0.5H₂O: C, 56.09; H, 4.34; N, 25.16. Found: C, 56.35; H, 4.01; N, 25.27.

30

Example 43N,N-[6-(4-phenylcyclohexyl)-1,3,5-triazin-2,4-diyil]bis[acetamide]

Example 3 was processed as in Example 33B to provide the title compound.

mp 235-236 °C;

35 MS (DCI/NH₃) m/e 354 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 10.61 (s, 2H), 7.30 (m, 4H), 7.18 (m, 1H), 2.63 (m, 1H), 2.56 (m, 1H), 2.36 (s, 6H), 1.98 (m, 4H), 1.63 (m, 4H);

Anal. calcd for $C_{19}H_{23}N_5O_2 \cdot 0.25H_2O$: C, 63.76; H, 6.62; N, 19.57. Found: C, 63.83; H, 6.52; N, 19.27.

Example 44

5 N-[4-amino-6-(4-phenylcyclohexyl)-1,3,5-triazin-2-yl]acetamide

Example 3 was processed as in Example 34 to provide the title compound.

mp > 260 °C;

MS (DCI/NH₃) m/e 312 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 10.02 (s, 1H), 7.28 (m, 7H), 2.54 (m, 1H), 2.44 (m,

10 1H), 2.25 (s, 3H), 1.96 (m, 4H), 1.59 (m, 4H);

Anal. calcd for $C_{17}H_{21}N_5O$: C, 65.57; H, 6.80; N, 22.49. Found: C, 65.37; H, 6.85; N,

22.74.

Example 45

15 6-(4-phenyl-1-naphthalenyl)-1,3,5-triazine-2,4-diamine

Example 45A

A solution of 4-methoxy-1-naphthalenecarbonitrile (3.5 g, 19 mmol) in dichloromethane (15 mL) at -78 °C was treated with BBr₃ (5 g, 20 mmol) in

20 dichloromethane (15 mL), stirred at room temperature for 18 hours, treated with AlCl₃ (5 g, 38 mmol), stirred at room temperature for 18 hours, treated with water and extracted with ethyl acetate. The extract was washed with water and brine, dried (MgSO₄), and concentrated. The residue was purified by flash chromatography on silica gel with 30% ethyl acetate/hexane to provide the designated compound.

25 MS (DCI/NH₃) m/e 187 (M+NH₄)⁺.

Example 45B

A solution of Example 45A (1.0 g, 5.9 mmol), triethylamine (1 mL, 7.2 mmol) and *N*-phenyl-trifluoromethanesulfonamide (2.1 g, 5.9 mmol) in dichloromethane (15 mL) 30 at 0 °C was stirred overnight at room temperature. The reaction was treated with ethyl acetate and washed sequentially with 10% HCl, 20% KOH, water, and brine, dried (MgSO₄), and concentrated to provide the designated compound.

MS (DCI/NH₃) m/e 319 (M+NH₄)⁺.

Example 45B and phenylboronic acid were processed as in Example 21 to provide the designated compound.

MS (DCI/NH₃) m/e 247 (M+NH₄)⁺.

5

Example 45D

6-(4-Phenyl-1-naphthalenyl)-1,3,5-triazine-2,4-diamine

Example 45C was processed as in Example 1 to provide the title compound.

mp 239-240 °C;

MS (DCI/NH₃) m/e 314 (M+H)⁺;

10 ¹H NMR (300 MHz, DMSO-d₆) δ 8.84-8.80 (m, 1H), 7.97 (d, 1H), 7.85-7.81 (m, 1H),

7.69-7.48 (m, 8H), 6.84 (bds, 4H);

Anal. calcd for C₁₉H₁₅N₅: C, 72.82; H, 4.82; N, 22.34. Found: C, 72.68; H, 4.77; N, 22.35.

15

Example 46

6-[4-(phenylthio)phenyl]-1,3,5-triazine-2,4-diamine

Example 46A

A solution of 4-bromobenzonitrile (1.0 g, 5.5 mmol), thiophenol (644 mg, 5.8 mmol), K₂CO₃ (1.9 g, 13.7 mmol) and CuI (1.05 g, 5.5 mmol) in DMF (20 mL) was heated at reflux for 24 hours, treated with ethyl acetate and filtered through Celite®. The filtrate was washed with water and brine, dried (MgSO₄), and concentrated. The residue was purified by flash chromatography on silica gel with 5% ethyl acetate/hexane to provide the designated compound.

25 MS (DCI/NH₃) m/e 229 (M+NH₄)⁺.

Example 46B

6-[4-(phenylthio)phenyl]-1,3,5-triazine-2,4-diamine

Example 46A was processed as in Example 1 to provide the title compound.

30 mp 213-215 °C;

MS (DCI/NH₃) m/e 296 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.19 (d, 2H), 7.44-7.41 (m, 5H), 7.32 (d, 2H), 6.77 (bds, 4H);

Anal. calcd for C₁₅H₁₃N₅S: C, 60.99; H, 4.43; N, 23.71. Found: C, 60.70; H, 4.32; N,

35 23.55.

Example 47

6-(2-quinolinyl)-1,3,5-triazine-2,4-diamine

2-Quinolinecarbonitrile was processed as in Example 1 to provide the title compound.

MS (DCI/NH₃) m/e 239 (M+H)⁺;

5 ¹H NMR (300 MHz, DMSO-d₆) δ 8.5 (d, 1H), 8.35 (d, 1H), 8.15-8.0 (m, 2H), 7.9-7.8 (m, 1H), 7.75-7.7 (m, 1H), 7.1-7.0 (br s, 2H), 7.0-6.9 (br s, 2H);
Anal. calcd for C₁₂H₁₀N₆: C, 60.49; H, 4.23; N, 35.27. Found: C, 60.24; H, 3.94; N, 35.12.

10

Example 486-(3-quinolinyl)-1,3,5-triazine-2,4-diamine

3-Quinolinecarbonitrile was processed as in Example 1 to provide the title compound.

mp > 250 °C;

15 MS (DCI/NH₃) m/e 239 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 9.7 (d, 1H), 9.1 (d, 1H), 8.2-8.1 (m, 2H), 6.9-6.85 (m, 1H), 6.8-6.7 (m, 1H), 7.05-6.9 (br s, 4H);
Anal. calcd for C₁₂H₁₀N₆: C, 60.49; H, 4.23; N, 35.27. Found: C, 60.32; H, 4.06; N, 35.54.

20

Example 496-(benzo[b]thien-2-ylmethyl)-1,3,5-triazine-2,4-diamine

Benzo[b]thiophene-2-acetonitrile was processed as in Example 1 to provide the title compound.

25 mp 216-218 °C;

MS (DCI/NH₃) m/e 258 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 7.97-7.92 (m, 1H), 7.87-7.80 (m, 1H), 7.48 (s, 1H), 7.4-7.32 (m, 2H), 6.65 (br s, 4H), 3.90 (s, 2H);

Anal. calcd for C₁₂H₁₁N₅S: C, 56.01; H, 4.30; N, 27.21. Found: C, 55.97; H, 4.19; N, 27.31.

Example 506-(2,2-dimethyl-2H-1-benzopyran-6-yl)-1,3,5-triazine-2,4-diamine

2,2-Dimethyl-2H-1-benzopyran-6-carbonitrile was processed as in Example 1 to provide the title compound.

35 MS (DCI/NH₃) m/e 270 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.05 (dd, 1H), 7.95 (d, 1H), 6.9 (d, 1H), 6.78-6.75 (br s, 4H), 6.70 (d, 1H), 5.80 (d, 1H), 1.20 (s, 6H);
 Anal. calcd for C₁₄H₁₅N₅O: C, 62.44; H, 5.61; N, 26.00. Found: C, 62.19; H, 5.70; N, 25.54.

5

Example 51

6-(2,3-dihydro-1,4-benzodioxin-2-yl)-1,3,5-triazine-2,4-diamine

2,3-Dihydro-1,4-benzodioxine-2-carbonitrile was processed as in Example 1 to provide the title compound.

10 MS (DCI/NH₃) m/e 246 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 7.0-6.75 (m, 8H), 3.5 (t, 1H), 3.3 (d, 2H);
 Anal. calcd for C₁₁H₁₁N₅O₂: C, 53.81; H, 4.52; N, 28.55. Found: C, 53.80; H, 4.36; N, 28.40.

15

Example 52

6-(tricyclo[3.3.1.1^{3,7}]decan-1-yl)-1,3,5-triazine-2,4-diamine

Methyl tricyclo[3.3.1.1^{3,7}]decane-1-carboxylate and Example 2B were processed as in Example 2C to provide the title compound.

mp 261-262 °C;
 20 MS (DCI/NH₃) m/e 246 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 6.47 (br s, 4H), 2.05-1.95 (m, 3H), 1.9-1.88 (m, 6H), 1.77-1.60 (m, 6H);
 Anal. calcd for C₁₃H₁₉N₅: C, 63.64; H, 7.80; N, 28.54. Found: C, 63.48; H, 7.66; N, 28.34.

25

Example 53

6-(1-isoquinoliny1)-1,3,5-triazine-2,4-diamine

1-Isoquinolinecarbonitrile was processed as in Example 1 to provide the title compound.

30 mp >250 °C;
 MS (DCI/NH₃) m/e 239 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 8.7 (d, 1H), 8.2 (d, 1H), 8.0 (d, 1H), 7.9 (d, 1H), 7.8 (dt, 1H), 7.65 (dt, 1H), 6.9 (bs, 4H);
 Anal. calcd for C₁₂H₁₀N₆·0.3H₂O: C, 60.49; H, 4.23; N, 35.27. Found: C, 59.55; H, 4.35; N, 34.03.

Example 54(+/-)-4-(4,6-diamino-1,3,5-triazine-2-yl)- α -phenylbenzenemethanol

5 A mixture of Example 11 (150 mg, 0.515 mmol) and sodium borohydride (6 mg, 0.15 mmol) in ethanol (5 mL) was heated at reflux for 30 minutes then stirred overnight at room temperature. The precipitate was rinsed with water and dried under vacuum to provide the title compound.

mp 214-216 °C;

MS (DCI/NH₃) m/e 294 (M+H)⁺;

10 ¹H NMR (300 MHz, DMSO-d₆) δ 8.2 (d, 2H), 7.5 (d, 2H), 7.4 (d, 2H), 7.3 (t, 2H), 7.2 (m, 1H), 6.7 (br s, 4H), 6.0 (d, 1H), 5.75 (d, 1H);

Anal. calcd for C₁₆H₁₅N₅O: C, 65.51; H, 5.15; N, 23.87. Found: C, 65.33; H, 4.91; N, 23.65.

Example 556-(2,3-dihydro-1,4-benzodioxin-6-yl)-1,3,5-triazine-2,4-diamine

2,3-Dihydro-1,4-benzodioxine-6-carbonitrile was processed as in Example 1 to provide the title compound.

mp 241-244 °C;

MS (DCI/NH₃) m/e 246 (M+H)⁺;

20 ¹H NMR (300 MHz, DMSO-d₆) δ 8.8-8.75 (m, 2H), 6.95-6.9 (m, 1H), 6.9-6.8 (br s, 4H), 4.25-4.33 (m, 4H);

Anal. calcd for C₁₁H₁₁N₅O₂: C, 53.87; H, 4.52; N, 28.56. Found: C, 53.93; H, 4.27; N, 28.41.

25

Example 566-(1-azabicyclo[2.2.2]octan-4-yl)-1,3,5-triazine-2,4-diamine

1-Azabicyclo[2.2.2]octane-4-carbonitrile was processed as in Example 1 to provide the title compound.

mp >245 °C;

30 MS (DCI/NH₃) m/e 221 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 6.6-6.5 (br s, 4H), 3.35 (s, 2H), 2.9 (t, 5H), 1.7 (t, 5H);

Anal. calcd for C₁₀H₁₆N₆: C, 54.53; H, 7.32; N, 38.15. Found: C, 54.40; H, 7.38; N, 38.25.

35

Example 576-[4-(phenylsulfinyl)phenyl]1,3,5-triazine-2,4-diamine

A mixture of Example 49 (102 mg, 0.34 mmol) and Oxone® (106 mg, 0.17 mmol) in acetic acid (2 mL) was stirred overnight at ambient temperature, treated with saturated NaHCO₃ and extracted with ethyl acetate. The extract was washed with water and brine, dried (MgSO₄), and concentrated. The residue was recrystallized from ethanol to provide

5 the title compound.

mp 253-255 °C;

MS (DCI/NH₃) m/e 312 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.36 (d, 2H), 7.81 (d, 2H), 7.75-7.72 (m, 2H), 7.60-7.52 (m, 3H), 6.82 (br s, 4H);

10 Anal. calcd for C₁₅H₁₃N₅OS·0.25H₂O: C, 57.03; H, 4.30; N, 22.17. Found: C, 57.47; H, 4.04; N, 21.81.

Example 58

6-[4-(phenylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine

15 4-(Phenylsulfonyl)benzonitrile (*J. Org. Chem.* 1989, 54, 4691) was processed as in Example 1, to provide the title compound.

mp >250 °C;

MS (DCI/NH₃) m/e 328 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.41 (d, 2H), 8.08 (d, 2H), 7.96 (d, 2H), 7.71-7.60 (m, 20 3H), 6.92 (br s, 4H);

Anal. calcd for C₁₅H₁₃N₅O₂S·0.25H₂O: C, 54.28; H, 4.10; N, 21.10. Found: C, 54.28; H, 3.92; N, 20.82.

Example 59

E/Z-[4-(4,6-diamino-1,3,5-triazine-2-yl)phenyl]phenylmethanone,oxime

A mixture of Example 11 (300 mg, 1.03 mmol) and hydroxylamine hydrochloride (70 mg, 1.0 mmol) in 1:1 ethanol/pyridine (10 mL) was heated at reflux for 3 hours, stirred overnight at room temperature, treated with water, and filtered. The precipitate was rinsed with water and dried to provide the title compound.

30 mp 97-107 °C;

MS (DCI/NH₃) m/e 307 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 11.42 (s, 0.5H), 11.41 (s, 0.5H), 8.35 (d, 1H), 8.2 (d, 1H), 7.3-7.5 (m, 7H), 6.8 (br s, 4H);

Anal. calcd for C₁₆H₁₄N₆O·CH₃CH₂OH: C, 61.35; H, 5.72; N, 23.84. Found: C, 61.67; 35 H, 5.29; N, 23.37.

Example 606-pyrazinyl-1,3,5-triazine-2,4-diamine

Pyrazinecarbonitrile was processed as in Example 1 to provide the title compound. mp>250 °C;

5 MS (DCI/NH₃) m/e 190 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 6.9 (br s, 2H), 7.1 (br s, 2H), 8.75-8.8 (m, 2H), 9.3 (s, 1H);
Anal. calcd for C₇H₇N₇: C, 44.44; H, 3.72; N, 51.82. Found: C, 44.40; H, 3.62; N, 51.79.

10

Example 612,4-diamino-6-[(4-phenylethenyl)phenyl]-1,3,5-triazineExample 61A

A solution of benzyltriphenylphosphonium chloride (22.8 g, 58 mmol) in THF (100 mL) at room temperature was treated with lithium hexamethyldisilazide (1M in toluene, 53 mL, 53 mmol), heated to reflux for 15 minutes, cooled to room temperature, treated with 4-cyanobenzaldehyde (7 g, 53 mmol) in THF (40 mL), stirred overnight at room temperature, acidified with 10% HCl, and filtered. The filtrate was extracted with ethyl acetate, dried (MgSO₄), and concentrated. The residue was dissolved in hot ethyl acetate and filtered through a plug of silica gel to provide the designated compound.

Example 61B

Example 61A was processed as in Example 1 to provide the title compound.

mp 216-217 °C;
25 MS (DCI/NH₃) m/e 290 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 8.25 (d, 2H), 7.75 (d, 2H), 7.65 (d, 2H), 7.2-7.4 (m, 5H), 6.75 (br s, 4H);
Anal. calcd for C₁₇H₁₅N₅·0.5CH₃CO₂CH₂CH₃: C, 68.45; H, 5.74; N, 21.00. Found: C, 68.50; H, 5.49; N, 21.43.

30

Example 622,4-diamino-6-[(4-(2-nitrophenyl)ethenyl)phenyl]-1,3,5-triazine

4-Nitrobenzyltriphenylphosphonium bromide was processed as in Examples 61A and 61B to provide the title compound.

35 mp >250 °C;
MS (DCI/NH₃) m/e 335 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.25 (t, 4H), 7.9 (d, 2H), 7.8 (d, 2H), 7.6 (m, 2H), 6.8 (br s, 4H);

Anal. calcd for C₁₇H₁₄N₆O₂: C, 61.07; H, 4.22; N, 25.14. Found: C, 60.78; H, 4.12; N, 24.89.

5

Example 63

6-[1,1'-biphenyl]-4-yl-N,N'-dimethyl-1,3,5-triazine-2,4-diamine

Example 63A

2-[1,1'-biphenyl]-4-yl-4,6-dichloro-1,3,5-triazine

A mixture of 4-phenyl-phenyl magnesium bromide (prepared from 4-bromobiphenyl (7.75 g, 33 mmol) and magnesium turnings (0.83 g, 35 mmol) in 40 mL ether) and cyanuric chloride (4.00 g, 21.7 mmol) in benzene (90 mL) was stirred at 0 °C for 90 minutes. The reaction was evaporated to dryness, and the residue was flash chromatographed on silica gel with 50% hexanes/methylene chloride to provide the desired compound (2.80 g, 43%).
MS (DCI/NH₃) m/e 301 (M+H)⁺.

Example 63B

6-[1,1'-biphenyl]-4-yl-N,N'-dimethyl-1,3,5-triazine-2,4-diamine

A mixture of Example 63A (0.52 g, 1.72 mmol) and N-methylamine (30 mmol) in tetrahydrofuran (25 mL) was stirred at ambient temperature for 72 hours. The reaction was reduced in volume and diluted with water. The precipitate was collected, rinsed with water and ether, and dried. Purification by reverse phase HPLC provided the desired compound.

mp 198-200 °C;

MS (DCI/NH₃) m/e 292 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.37 (m, 2H), 7.74 (m, 4H), 7.51 (m, 2H), 7.39 (m, 1H), 7.22 (bdm, 2H), 2.82 (m, 6H);

Anal. calcd for C₁₇H₁₇N₅•0.25 H₂O: C, 69.01; H, 5.96; N, 23.67. Found: C, 69.37; H, 5.85; N, 23.63.

30

Example 64

6-[1,1'-biphenyl]-4-yl-N-methyl-1,3,5-triazine-2,4-diamine

Example 64A

4-[1,1'-biphenyl]-4-yl-6-chloro-1,3,5-triazin-2-amine

A mixture of 2-[1,1'-biphenyl]-4-yl-4,6-dichloro-1,3,5-triazine (Example 63A) (0.804 g, 2.67 mmol) in 40 mL ether and concentrated ammonium hydroxide (2 mL, 30 mmol) in tetrahydrofuran (30 mL) was stirred at 0 °C for 60 minutes and at ambient temperature for 20 minutes. The reaction was reduced in volume, diluted with water, and 5 the precipitate was collected, rinsed with water and ether, and dried to provide the desired compound (0.090 g, 12%).

MS (DCI/NH₃) m/e 282 (M+H)⁺.

Example 64B

6-[1,1'-biphenyl]-4-yl-N-methyl-1,3,5-triazine-2,4-diamine

Example 64A (0.090 g, 0.32 mmol) and *N*-methylamine (6 mmol) in tetrahydrofuran (9 mL) was stirred at ambient temperature for 24 hours. The reaction was reduced in volume and diluted with water. The precipitate was collected, rinsed with water and ether, and dried to provide the desired compound (0.062 g, 70%).

mp 237-238 °C;

15 MS (DCI/NH₃) m/e 278 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.39 (d, 1H), 8.32 (d, 1H), 7.77 (m, 4H), 7.51 (t, 2H), 7.41 (m, 1H), 7.25 (q, 1H), 6.79 (bds, 2H), 2.79 (d, 3H);

Anal. calcd for C₁₆H₁₅N₅•0.5 C₄H₈O₂: C, 67.27; H, 5.96; N, 21.79. Found: C, 67.20; H, 5.71; N, 22.05.

20

Example 65

6-(bicyclo[2.2.1]hept-2-yl)-1,3,5-triazine-2,4-diamine

Example 65A

6-(bicyclo[2.2.1]hept-2-en-5-yl)-1,3,5-triazine-2,4-diamine

Bicyclo[2.2.1]hept-2-ene-5-carbonitrile was processed as in Example 1 to provide the desired compound.

MS (DCI/NH₃) m/e 204 (M+H)⁺

Example 65B

6-(bicyclo[2.2.1]hept-2-yl)-1,3,5-triazine-2,4-diamine

A solution of Example 65A in methanol was reduced with hydrogen gas and palladium on charcoal, filtered, and evaporated to provide the desired compound.

mp 216-217 °C;

MS (DCI/NH₃) m/e 206 (M+H)⁺;

35 ¹H NMR (300 MHz, DMSO-d₆) δ 6.52 (bds, 4H), 2.83 (m, 1H), 2.39 (m, 1H), 2.21 (m, 1H), 2.04 (m, 1H), 1.91 (m, 1H), 1.6-1.2 (m, 5H), 6.52 (m, 1H);

Anal. calcd for C₁₀H₁₅N₅: C; 58.52, H; 7.37, N; 34.12. Found: C; 58.59, H; 7.40, N; 34.00.

Example 66

6-[1,1'-biphenyl]-4-yl-N,N'-diethyl-1,3,5-triazine-2,4-diamine

A mixture of 2,4-di-N-ethylamino-6-chloro-1,3,5-triazine (0.55 g, 2.7 mmol) and tetrakis(triphenylphosphine) palladium (0.19 g, 0.16 mmol) in dry, degassed dimethylacetamide (45 mL) was heated to 100 °C, treated sequentially with 4-(phenyl)phenyl boronic acid (Yabroff et al., *Journal of the American Chemical Society*, Volume 56, 1934, pp.1850-1856) (0.80 g, 4.0 mmol) in absolute ethanol (15 mL) and saturated aqueous sodium bicarbonate (30 mL), and the reaction mixture was maintained at 100 °C for 3 days. The reaction mixture was cooled to room temperature and diluted with ethyl acetate. The organic layer was washed with brine, dried (MgSO₄), concentrated, and vacuum dried. The residue was recrystallized from 2:1 dioxane/ethanol to provide 0.15 g (17%) of the desired compound as a white solid.

mp 183-184 °C;

MS (DCI/NH₃) m/e 320 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.36 (m, 2H), 7.78 (d, 2H), 7.73 (d, 2H), 7.49 (m, 2H), 7.38 (m, 1H), 7.28 (m, 2H), 3.40 (m, 4H), 1.16 (m, 6H);

Anal. calcd for C₁₉H₂₁N₅•0.2 C₄H₈O₂: C, 70.91; H, 6.55; N, 8.28. Found: C, 71.21; H, 6.50; N, 21.13.

Example 67

6-(2'-nitro[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine

4-Cyano-2'-nitrobiphenyl was processed as in Example 1 to provide the desired compound.

mp >250 °C;

¹H NMR (300 MHz, DMSO-d₆) δ 8.3 (d, 2H, J=9 Hz), 8.05 (dd, 1H), 7.8 (m, 1H), 7.6-7.7 (m, 2H), 7.45 (d, 2H), 6.8 (br s, 4H);

MS (DCI/NH₃) m/e 309 (M+H)⁺;

Anal. calcd for C₁₅H₁₂N₆O₂: C, 58.44; H, 3.92; N, 27.26. Found: C, 58.46; H, 3.99; N, 27.15.

Example 68

6-(6-methyl-3-pyridinyl)-1,3,5-triazine-2,4-diamine

6-Methylnicotinonitrile was processed as in Example 1 to provide the desired compound.

mp >260 °C;

MS (DCI/NH₃) m/e 203 (M+H)⁺;

5 ¹H NMR (300 MHz, DMSO-d₆) δ 9.23 (d, 1H), 8.39 (dd, 1H, J=11), 7.38 (d, 1H), 6.81 (br s, 4H), 2.56 (s, 3H);
Anal. calcd for C₉H₁₀N₆: C, 53.45; H, 4.98; N, 41.55. Found: C, 53.46; H, 4.94; N, 41.84.

10

Example 69

6-(6-chloro-3-pyridinyl)-1,3,5-triazine-2,4-diamine

Methyl 6-chloronicotinate and imidodicarbonimidic diamide (2B) was processed as in Example 2C to provide the desired compound.

mp >260 °C;

15 MS (DCI/NH₃) m/e 223, 225 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 9.17 (d, 1H), 8.46 (dd, 1H, J=11), 7.62 (d, 1H), 6.91 (br s, 4H);
Anal. calcd for C₈H₇ClN₆: C, 43.15; H, 3.16; N, 37.74. Found: C, 43.05; H, 3.08; N, 37.50.

20

Example 70

6-(5-bromo-3-pyridinyl)-1,3,5-triazine-2,4-diamine

5-Bromonicotinonitrile was processed as in Example 1 to provide the desired compound.

25 mp >260 °C;

MS (DCI/NH₃) m/e 267 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 9.3 (d, 1H), 8.82 (d, 1H, J=3 Hz), 8.62-8.64 (m, 1H), 6.8-7.1 (br s, 1H);

Anal. calcd for C₈H₇BrN₆: C, 35.98; H, 2.64; N, 31.47. Found: C, 35.89; H, 2.53; N, 31.22.

Example 71

6-(2,3-dihydro-2,2,3,3-tetrafluoro-1,4-benzodioxin-6-yl)-1,3,5-triazine-2,4-diamine

6-Cyano-2,3-dihydro-2,2,3,3-tetrafluoro-1,4-benzodioxane was processed as in Example 1 to provide the desired compound.

mp 176-179 °C;

MS (DCI/NH₃) m/e 275 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 7.98 (d, 1H), 7.71 (d, 1H), 7.17 (dd, 1H), 7.16 (br s, 2H), 6.95 (br s, 2H), 3.85 (s, 3H);
Anal. calcd for C₁₁H₇F₄N₅O₂: C; 41.65, H; 2.22, N; 22.08. Found: C; 41.55, H; 2.10, N; 22.09.

5

Example 726-[4-[(4-chlorophenyl)methoxy]phenyl]-1,3,5-triazine-2,4-diamine

4-[(4-Chlorophenyl)methoxy]benzonitrile was processed as in Example 1 to provide the desired compound.

10 mp 246-248 °C;
MS (DCI/NH₃) m/e 342 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 7.45 (s, 4H), 7.25 (d, 2H), 6.9 (d, 2H), 6.6 (br s, 4H), 5.05 (s, 2H), 3.55 (s, 2H);
Anal. calcd for C₁₇H₁₆ClN₅O: C, 59.74; H, 4.72; N, 20.49. Found: C, 59.64; H, 4.64; N, 20.49.

15

Example 736-[4-(1-piperidinylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine20 Example 73A1-[(4-cyanophenyl)sulfonyl]piperidine

A mixture of 4-cyanobenzenesulfonyl chloride (0.51 g, 2.5 mmol) and piperidine (0.60 mL, 517 mg, 6.04 mmol) in 10 mL methylene chloride was stirred overnight at ambient temperature. The organic layer was washed successively with water, 5% HCl and 25 brine, dried (Na₂SO₄) and concentrated. The resulting white solid (0.61 g, 96%) was used with no further purification.

Example 73B6-[4-(1-piperidinylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine

The product of Example 73A was processed as in Example 1 to provide the desired compound.

30 m.p. >260 °C;
MS (DCI/NH₃) m/e 335 (M+H)⁺;
¹H NMR (300 MHz, DMSO-d₆) δ 8.43 (d, 2H), 7.84 (d, 2H), 6.90 (bds, 4H), 2.90-2.97 (m, 4H), 1.50-1.59 (m, 4H), 1.32-1.42 (m, 2H);
35 Anal. calcd for C₁₄H₁₈N₆O₂S: C, 50.28; H, 5.42; N, 25.13. Found: C, 50.43; H, 5.32; N, 25.12.

Example 746-(1-benzoyl-4-piperidinyl)-1,3,5-triazine-2,4-diamine

5

Example 74A1-benzoyl-4-piperidinecarbonitrile

A mixture of 1-benzoyl-4-piperidone (2.0 g, 9.8 mmol), tosylmethyl isocyanide (2.5 g, 12.8 mmol) and ethanol (1.0 mL, 17.1 mmol) in 30 mL DME was cooled in an ethanol/ice bath, and potassium tert-butoxide was added at such a rate to maintain the reaction temperature at <10 °C. The cold bath was removed, and the reaction was allowed to stir overnight at room temperature. The solids were removed by filtration, rinsed with DME, and the filtrate was evaporated. The residue was dissolved in EtOAc, washed with water and brine, dried (MgSO₄), filtered through silica gel, and concentrated to give 2.14 g (66%) of a slightly yellow oil.

15

Example 74B6-(1-benzoyl-4-piperidinyl)-1,3,5-triazine-2,4-diamine

The product of Example 74A was processed as in Example 1 to provide the desired compound.

20 m.p. 246-248 °C;

MS (DCI/NH₃) m/e 299 (M+H)⁺;¹H NMR (300 MHz, DMSO-d₆) δ 7.43-7.49 (m, 3H), 7.33-7.39 (m, 2H), 6.58 (bds, 4H),

4.44-4.52 (bm, 1H), 3.55-3.67 (bm, 1H), 2.79-3.27 (bm, 2H), 1.53-1.94 (bm, 5H);

Anal. calcd for C₁₅H₁₈N₆O: C, 60.38; H, 6.08; N, 28.16. Found: C, 60.09; H, 6.02; N,

25 28.29.

Example 756-[1-(phenylmethyl)-4-piperidinyl]-1,3,5-triazine-2,4-diamine

N-Benzyl-4-piperidone was processed as in example 74A and 74B to provide the desired compound.

30 m.p. >260 °C;

MS (DCI/NH₃) m/e 285 (M+H)⁺;¹H NMR (300 MHz, DMSO-d₆) δ 7.19-7.32 (m, 5H), 6.50 (bds, 4H), 3.44 (s, 2H), 2.78-

2.86 (m, 2H), 2.16-2.28 (m, 1H), 1.90-1.99 (m, 2H), 1.63-1.76 (m, 4H);

35 Anal. calcd for C₁₅H₂₀N₆•H₂O: C, 59.58; H, 7.33; N, 27.79. Found: C, 60.06; H, 7.19; N, 27.94.

Example 76N,N'-diacetyl-6-[4-(phenylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine

6-[4-(phenylsulfonyl)phenyl]1,3,5-triazine-2,4-diamine (Example 58) was

5 processed as in Example 33B to provide the desired compound.

mp > 260 °C;

MS (DCI/NH₃) m/e 412 (M+H)⁺;

¹H NMR (300 MHz, DMSO-d₆) δ 8.52 (d, 2H, J=8 Hz), 8.18 (d, 2H, J=8 Hz), 8.01 (m, 2H), 7.73 (m, 1H), 7.68 (m, 2H), 2.37 (s, 6H);

10 Anal. calcd for C₁₉H₁₇N₅O₄: C, 55.47; H, 4.16; N, 17.02. Found: C, 55.47; H, 4.19; N, 17.11.

Example 77N-acetyl-6-[4-(phenylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine

15 6-[4-(phenylsulfonyl)phenyl]1,3,5-triazine-2,4-diamine (Example 58) was processed as in Example 34 to provide the desired compound.

mp > 260 °C;

MS (DCI/NH₃) m/e 370 (M+H)⁺;

¹H NMR (300 MHz, CF₃CO₂D) δ 8.51 (d, 2H), 8.27 (d, 2H), 8.06 (d, 2H), 7.78 (t, 1H), 7.68 (t, 2H), 2.56 (s, 3H);

20 Anal. calcd for C₁₇H₁₅N₅O₃•0.5 H₂O: C, 53.96; H, 4.26; N, 18.51. Found: C, 53.75; H, 3.91; N, 18.83.

Example 786-[2-(1-piperidinyl)phenyl]-1,3,5-triazine-2,4-diamine

25 2-(1-piperidinyl)benzonitrile was processed as in Example 1 to provide the desired compound.

mp >250 °C;


MS (DCI/NH₃) m/e 271 (M+H)⁺;

30 ¹H NMR (300 MHz, DMSO-d₆) δ 7.27 (d, 2H), 6.93 (d, 2H), 6.89 (m, 1H), 6.63 (bds, 4H), 3.88 (m, 4H), 1.47 (bdm, 6H);

Anal. calcd for C₁₄H₁₈N₆: C; 62.20, H; 6.71, N; 31.09. Found: C; 61.88, H; 6.36, N; 31.37.

WHAT IS CLAIMED IS:

1. Compounds having Formula I,



5 or pharmaceutically acceptable salts or prodrugs thereof, wherein
 R₁, R₂, R₃, and R₄ are independently selected from the group
 consisting of hydrogen, C₁-C₂₀ alkyl, and C₁-C₂₀ alkanoyl; or

10 R₁ and R₂ together with the nitrogen atom to which they are attached
 form a ring independently selected from the group consisting of morpholine,
 piperidine, piperazine, and pyrrolidine; or

R₃ and R₄ together with the nitrogen atom to which they are attached
 form a ring independently selected from the group consisting of morpholine,
 piperidine, piperazine, and pyrrolidine;

15 A is selected from the group consisting of heterocycle,
 (heterocycle)-C₁-C₂₀-alkyl, C₃-C₁₀ cycloalkyl, C₆-C₁₅ spiroalkyl, and
 -B-L-Y;

B and Y are independently aryl, C₃-C₁₀ cycloalkyl,
 C₄-C₁₀ cycloalkenyl, heterocycle, or C₆-C₁₅ spiroalkyl;

20 L is a covalent bond, -C(=W)-, C₁-C₂₀ alkylene, -NR₅-,
 -NR₆C(X)NR₇-, C₂-C₂₀ alkynylene, C₂-C₂₀, alkenylene, -O-, -S(O)_t-,
 -NR₆C(X)-, -C(X)NR₆-, -NR₆SO₂NR₇-, -NR₆SO₂-, -SO₂NR₆-, or
 -O(CR₁R₂)-;

25 R₅ is hydrogen, C₁-C₂₀ alkyl, C₁-C₂₀ alkanoyl, and C₁-C₂₀ arylalkyl;
 R₆ and R₇ are independently hydrogen, C₁-C₂₀ alkyl, and
 aryl-C₁-C₂₀-alkyl;

R₁ and R₂ are previously defined;

W is O, S, or (=N-O-R₆);

X is O or S;

t is 0-2;

30 each L is shown with its left end attached to B and its right end attached to Y; and
 at each occurrence, aryl, cycloalkyl, cycloalkenyl, heterocycle, spiroalkyl, alkylene, and (heterocycle)alkyl may be optionally substituted with 1-3 substituents independently selected from C₁-C₂₀ alkoxy, C₁-C₂₀ alkyl, amino, 35 aryl, azido, cyano, halo, C₁-C₂₀ haloalkyl, heterocycle, nitro, or R₁₀ and R₁₁

wherein R₁₀ and R₁₁ together are  wherein A and D are independently oxygen or S(O)_t and n is 2-3,

40 with the proviso that when B and Y are unsubstituted phenyl and L is a covalent bond, then at least one of R₁, R₂, R₃, and R₄ is other than hydrogen, and

with the proviso that when L is a covalent bond and one of B or Y is unsubstituted imidazole and the other is unsubstituted phenyl, then at least one of R₁, R₂, R₃, and R₄ is other than hydrogen.

2. A compound selected from the group consisting of
 6-[1-(diphenylmethyl)-3-azetidinyl]-1,3,5-triazine-2,4-diamine,
 6-(1-phenyl-4-piperidinyl)-1,3,5-triazine-2,4-diamine,
 trans-6-(4-phenylcyclohexyl)-1,3,5-triazine-2,4-diamine,
 5 6-[3-(1H-pyrrol-1-yl)phenyl]-1,3,5-triazine-2,4-diamine,
 cis/trans-6-(3-phenylcyclobutyl)-1,3,5-triazine-2,4-diamine,
 6-[1,1'-biphenyl]-2-yl-1,3,5-triazine-2,4-diamine,
 6-(4'-nitro[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
 6-[4-(4-pentylcyclohexyl)phenyl]-1,3,5-triazine-2,4-diamine,
 10 6-(4-phenoxyphenyl)-1,3,5-triazine-2,4-diamine,
 N-cyclohexyl-N'-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]urea,
 (4,6-diamino-1,3,5-triazine-2-yl)phenylmethenone,
 N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]-N'-phenyl urea,
 15 6-(1,4-dioxa-8-azaspiro[4,5]dec-8-yl)-1,3,5-triazine-2,4-diamine,
 6-(4'-pentyl[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
 6-[4'-(pentyloxy)[1,1'-biphenyl]-4-yl]-1,3,5-triazine-2,4-diamine,
 6-(6-methoxy-2-benzothiazolyl)-1,3,5-triazine-2,4-diamine,

6-(4'-amino[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
 6-[4-(5-oxazolyl)phenyl]-1,3,5-triazine-2,4-diamine,
 20 6-[4-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]-1,3,5-triazine-2,4-diamine,
 4'-(4,6-diamino-1,3,5-triazine-2-yl)[1,1'-biphenyl]-4-carbonitrile,
 6-(4'-methoxy[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
 6-(4'-fluoro[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine
 25 *N*-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]benzenesulfonamide,
 6-[1-([1,1'-biphenyl]-4-yl)-4-piperidinyl]-1,3,5-triazine-2,4-diamine,
N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]-2-naphthalenesulfonamide,
 2,5-dichloro-*N*-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]benzenesulfonamide,
 6-(1-phenylcyclohexyl)-1,3,5-triazine-2,4-diamine,
 6-[1-(4-methoxyphenyl)-4-piperidinyl]-1,3,5-triazine-2,4-diamine,
 30 6-[2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]-1,3,5-triazine-2,4-diamine,
 6-[1-(4-methoxyphenyl)cyclohexyl]-1,3,5-triazine-2,4-diamine,
 6-[4-(2-thienyl)phenyl]-1,3,5-triazine-2,4-diamine,
 6-[4-(phenylethynyl)phenyl]-1,3,5-triazine-2,4-diamine,
 35 *N,N'*-(6-[1,1'-biphenyl]-4-yl-1,3,5-triazin-2,4-diyl)bis[acetamide],
N-(4-amino-6-[1,1'-biphenyl]-4-yl-1,3,5-triazin-2-yl)acetamide,
N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]-1-naphthalenesulfonamide,
 6-(4'-azido[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
 6-[4-(4-morpholinylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine,
 6-[4-(2-furanyl)phenyl]-1,3,5-triazine-2,4-diamine,
 40 *N,N'*-[6-(4-phenoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[acetamide],
N-[4-amino-6-(4-phenoxyphenyl)-1,3,5-triazin-2-yl]acetamide,
 6-(5-phenyl-2-furanyl)-1,3,5-triazine-2,4-diamine,
 6-(5-phenyl-2-thienyl)-1,3,5-triazine-2,4-diamine,
N,N'-[6-(4-phenylcyclohexyl)-1,3,5-triazin-2,4-diyl]bis[acetamide],
 45 *N*-[4-amino-6-(4-phenylcyclohexyl)-1,3,5-triazin-2-yl]acetamide,
 6-(4-phenyl-1-naphthalenyl)-1,3,5-triazine-2,4-diamine,
 6-[4-(phenylthio)phenyl]-1,3,5-triazine-2,4-diamine,
 6-(2-quinolinyl)-1,3,5-triazine-2,4-diamine,
 6-(3-quinolinyl)-1,3,5-triazine-2,4-diamine,
 50 6-(benzo[b]thien-2-ylmethyl)-1,3,5-triazine-2,4-diamine,
 6-(2,2-dimethyl-2H-1-benzopyran-6-yl)-1,3,5-triazine-2,4-diamine,

6-(1-isoquinolinyl)-1,3,5-triazine-2,4-diamine
(6-(2,3-dihydro-1,4-benzodioxin-2-yl)-1,3,5-triazine-2,4-diamine,
6-(tricyclo[3.3.1.1³.7]decan-1-yl)-1,3,5-triazine-2,4-diamine,
55 (+/-)-4-(4,6-diamino-1,3,5-triazine-2-yl)- α -phenylbenzenemethanol,
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-1,3,5-triazine-2,4-diamine,
6-(1-azabicyclo[2.2.2]octan-4-yl)-1,3,5-triazine-2,4-diamine,
6-[4-(phenylsulfinyl)phenyl]1,3,5-triazine-2,4-diamine,
6-[4-(phenylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine,
60 [4-(4,6-diamino-1,3,5-triazine-2-yl)phenyl]phenylmethanone, oxime,
6-pyrazinyl-1,3,5-triazine-2,4-diamine,
2,4-diamino-6-[(4-phenylethenyl)phenyl]-1,3,5-triazine,
2,4-diamino-6-[(4-(2-nitrophenyl)ethenyl)phenyl]-1,3,5-triazine,
65 6-[1,1'-biphenyl]-4-yl-*N,N'*-dimethyl-1,3,5-triazine-2,4-diamine,
6-[1,1'-biphenyl]-4-yl-*N*-methyl-1,3,5-triazine-2,4-diamine,
6-(bicyclo[2.2.1]hept-2-yl)-1,3,5-triazine-2,4-diamine,
6-[1,1'-biphenyl]-4-yl-*N,N'*-diethyl-1,3,5-triazine-2,4-diamine,
6-(2'-nitro[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
6-(6-methyl-3-pyridinyl)-1,3,5-triazine-2,4-diamine,
70 6-(6-chloro-3-pyridinyl)-1,3,5-triazine-2,4-diamine,
6-(5-bromo-3-pyridinyl)-1,3,5-triazine-2,4-diamine,
6-(2,3-dihydro-2,2,3,3-tetrafluoro-1,4-benzodioxin-6-yl)-1,3,5-triazine-2,4-
diamine,
6-[4-[(4-chlorophenyl)methoxy]phenyl]-1,3,5-triazine-2,4-diamine,
75 6-[4-(1-piperidinylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine,
6-(1-benzoyl-4-piperidinyl)-1,3,5-triazine-2,4-diamine,
6-[1-(phenylmethyl)-4-piperidinyl]-1,3,5-triazine-2,4-diamine,
N,N'-diacetyl-6-[4-(phenylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine,
80 *N*-acetyl-6-[4-(phenylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine, and
6-(2-piperidin-1-ylphenyl)-1,3,5-triazine-2,4-diamine.

3. A compound according to Claim 1 wherein R₁, R₂, R₃, and R₄ are hydrogen.
4. A compound according to Claim 3 wherein A is heterocycle,

(heterocycle)-C₁-C₂₀-alkyl, C₃-C₂₀ cycloalkyl, and C₆-C₁₅ spiroalkyl wherein the heterocycle, (heterocycle)-C₁-C₂₀-alkyl, cycloalkyl, (heterocycle)alkyl and spiroalkyl may be optionally substituted.

5. A compound according to Claim 4 selected from the group consisting of 6-(1,4-dioxa-8-azaspiro[4,5]dec-8-yl)-1,3,5-triazine-2,4-diamine, 6-(2-quinolinyl)-1,3,5-triazine-2,4-diamine, 6-(3-quinolinyl)-1,3,5-triazine-2,4-diamine, 6-(benzo[b]thien-2-ylmethyl)-1,3,5-triazine-2,4-diamine, 6-(2,2-dimethyl-2H-1-benzopyran-6-yl)-1,3,5-triazine-2,4-diamine, 6-(2,3-dihydro-1,4-benzodioxin-2-yl)-1,3,5-triazine-2,4-diamine, 6-(tricyclo[3.3.1.1^{3,7}]decan-1-yl)-1,3,5-triazine-2,4-diamine, 6-(1-isoquinolinyl)-1,3,5-triazine-2,4-diamine, 10 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-1,3,5-triazine-2,4-diamine, 6-(1-azabicyclo[2.2.2]octan-4-yl)-1,3,5-triazine-2,4-diamine, 6-pyrazinyl-1,3,5-triazine-2,4-diamine, 6-(6-Methoxy-2-benzothiazolyl)-1,3,5-triazine-2,4-diamine, 6-(5-bromo-3-pyridinyl)-1,3,5-triazine-2,4-diamine, 15 6-(6-chloro-3-pyridinyl)-1,3,5-triazine-2,4-diamine, 6-(2,3-dihydro-2,2,3,3-tetrafluoro-1,4-benzodioxin-6-yl)-1,3,5-triazine-2,4-diamine, and 6-(6-methyl-3-pyridinyl)-1,3,5-triazine-2,4-diamine.
6. A compound according to Claim 3 wherein A is -B-L-Y or C₃-C₁₀ cycloalkyl, B and Y are independently aryl, C₃-C₁₀ cycloalkyl, C₄-C₁₀ cycloalkenyl, C₆-C₁₅ spiroalkyl, or heterocycle, and the aryl, cycloalkyl, cycloalkenyl, spiroalkyl, or heterocycle may be optionally substituted.
7. A compound according to Claim 6 wherein L is a covalent bond or alkylene.
8. A compound according to Claim 7 selected from the group consisting of 6-[1-(diphenylmethyl)-3-azetidinyl]-1,3,5-triazine-2,4-diamine, 6-(1-phenyl-4-piperidinyl)-1,3,5-triazine-2,4-diamine, trans-6-(4-phenylcyclohexyl)-1,3,5-triazine-2,4-diamine, 5 6-[3-(1H-pyrrol-1-yl)phenyl]-1,3,5-triazine-2,4-diamine,

cis/trans-6-(3-phenylcyclobutyl)-1,3,5-triazine-2,4-diamine,
 6-[1,1'-biphenyl]-2-yl-1,3,5-triazine-2,4-diamine,
 6-(4'-nitro[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
 6-[4-(4-pentylcyclohexyl)phenyl]-1,3,5-triazine-2,4-diamine,
 10 6-(4'-pentyl[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
 6-[4'-(pentyloxy)[1,1'-biphenyl]-4-yl]-1,3,5-triazine-2,4-diamine,
 6-(4'-amino[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine
 6-[4-(5-oxazolyl)phenyl]-1,3,5-triazine-2,4-diamine,
 15 4'-(4,6-diamino-1,3,5-triazine-2-yl)[1,1'-biphenyl]-4-carbonitrile,
 6-(4'-methoxy[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
 6-(4'-fluoro[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
 6-[1-([1,1'-biphenyl]-4-yl)-4-piperidinyl]-1,3,5-triazine-2,4-diamine,
 20 6-(1-phenylcyclohexyl)-1,3,5-triazine-2,4-diamine,
 6-[1-(4-methoxyphenyl)-4-piperidinyl]-1,3,5-triazine-2,4-diamine,
 6-[2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]-1,3,5-triazine-2,4-diamine,
 6-[1-(4-methoxyphenyl)cyclohexyl]-1,3,5-triazine-2,4-diamine,
 25 6-[4-(2-thienyl)phenyl]-1,3,5-triazine-2,4-diamine,
 6-(4'-azido[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine,
 6-[4-(2-furanyl)phenyl]-1,3,5-triazine-2,4-diamine,
 6-(5-phenyl-2-furanyl)-1,3,5-triazine-2,4-diamine,
 6-(5-phenyl-2-thienyl)-1,3,5-triazine-2,4-diamine,
 6-(4-phenyl-1-naphthalenyl)-1,3,5-triazine-2,4-diamine,
 30 6-(bicyclo[2.2.1]hept-2-yl)-1,3,5-triazine-2,4-diamine,
 6-(2-piperidin-1-ylphenyl)-1,3,5-triazine-2,4-diamine,
 6-[1-(phenylmethyl)-4-piperidinyl]-1,3,5-triazine-2,4-diamine, and
 6-(2'-nitro[1,1'-biphenyl]-4-yl)-1,3,5-triazine-2,4-diamine.

9. A compound according to Claim 6 wherein L is -O- or -O(CR₁R₂)-, wherein R₁ and R₂ are previously defined.

10. A compound according to Claim 9 selected from the group consisting of 6-(4-phenoxyphenyl)-1,3,5-triazine-2,4-diamine,
 6-[4-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]-1,3,5-triazine-2,4-diamine,
 and

5 6-[4-[(4-chlorophenyl)methoxy]phenyl]-1,3,5-triazine-2,4-diamine.

11. A compound according to Claim 6 wherein L is -NR₆SO₂- and R₆ is hydrogen.

12. A compound according to Claim 11 selected from the group consisting of N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]benzenesulfonamide, N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]-2-naphthalenesulfonamide, 2,5-dichloro-N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]benzenesulfonamide, and N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]-1-naphthalenesulfonamide.

5 13. A compound according to Claim 6 wherein L is -NR₆C(X)NR₇-, X is O, and R₆ and R₇ are hydrogen.

14. A compound according to Claim 13 selected from the group consisting of N-cyclohexyl-N'-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]urea and N-[4-(4,6-diamino-1,3,5-triazin-2-yl)phenyl]-N'-phenyl urea.

15. A compound according to Claim 6 wherein L is C₂-C₂₀ alkynylene.

16. A compound according to Claim 15 which is 6-[4-(phenylethynyl)phenyl]-1,3,5-triazine-2,4-diamine.

17. A compound according to Claim 6 wherein L is C₂-C₂₀ alkenylene.

18. A compound according to Claim 17 selected from the group consisting of (E)-2,4-diamino-6-[4-(2-(4-nitrophenyl)ethenyl)phenyl]-1,3,5-triazine and (E)-2,4-diamino-6-[4-(2-phenylethenyl)phenyl]-1,3,5-triazine.

19. A compound according to Claim 6 wherein L is -S(O)_t- and t is 0-2.

20. A compound according to Claim 19 selected from the group consisting of 6-[4-(4-morpholinylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine, 6-[4-(phenylthio)phenyl]-1,3,5-triazine-2,4-diamine, 6-[4-(phenylsulfinyl)phenyl]-1,3,5-triazine-2,4-diamine, 6-[4-(Phenylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine, and

5

6-[4-(1-piperidinylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine.

21. A compound according to Claim 6 wherein L is -C(W)- and W is (=O), (=S), or (=N-O-R₆).
22. A compound according to Claim 21 selected from the group consisting of (E/Z)-2,4-diamino-6-[(4-benzoyl)phenyl]-1,3,5-triazine oxime, (4,6-Diamino-1,3,5-triazine-2-yl)phenylmethenone, (+/-)-4-(4,6-diamino-1,3,5-triazine-2-yl)- α -phenylbenzenemethanol, and 6-(1-benzoyl-4-piperidinyl)-1,3,5-triazine-2,4-diamine.
23. A compound according to Claim 1 wherein R₁, R₂, R₃, and R₄ are independently hydrogen, C₁-C₂₀ alkyl or C₁-C₂₀ alkanoyl.
24. A compound according to Claim 23 wherein A is -B-L-Y, B and Y are independently aryl, C₃-C₁₀ cycloalkyl, C₄-C₁₀cycloalkenyl, C₆-C₁₅ spiroalkyl, or heterocycle, and the aryl, cycloalkyl, cycloalkenyl, spiroalkyl, or heterocycle may be optionally substituted.
25. A compound according to Claim 24 wherein L is a covalent bond.
26. A compound according to Claim 25 selected from the group consisting of N,N'-(6-[1,1'-biphenyl]-4-yl-1,3,5-triazin-2,4-diyl)bis[acetamide], N-(4-amino-6-[1,1'-biphenyl]-4-yl-1,3,5-triazin-2-yl)acetamide, N,N'-[6-(4-phenylcyclohexyl)-1,3,5-triazin-2,4-diyl]bis[acetamide], N-[4-amino-6-(4-phenylcyclohexyl)-1,3,5-triazin-2-yl]acetamide, 6-[1,1'-biphenyl]-4-yl-N,N'-diethyl-1,3,5-triazine-2,4-diamine, 6-[1,1'-biphenyl]-4-yl-N,N'-dimethyl-1,3,5-triazine-2,4-diamine, 6-[1,1'-biphenyl]-4-yl-N-methyl-1,3,5-triazine-2,4-diamine, N,N'-diacetyl-6-[4-(phenylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine, and N-acetyl-6-[4-(phenylsulfonyl)phenyl]-1,3,5-triazine-2,4-diamine.
27. A compound according to Claim 23 wherein L is -O-.
28. A compound according to Claim 27 selected from the group consisting of N,N'-[6-(4-phenoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[acetamide] and

N-[4-amino-6-(4-phenoxyphenyl)-1,3,5-triazin-2-yl]acetamide.

29. A method of ameliorating angiogenic diseases comprising administering a compound of Claim 1.
30. A method according to Claim 29 wherein the disease is selected from the group consisting of cancer, diabetic retinopathy, and macular degeneration.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/26369

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6	C07D403/04	A61K31/53	C07D401/04	C07D251/18	C07D417/04
	C07D413/10	C07D401/12	C07D409/10	C07D407/10	C07D407/04
	C07D409/04	C07D409/06	C07D405/04	C07D453/02	C07D401/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^o	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>HORI, TAKAAKI ET AL: "Triazine derivatives inhibit rat hepatocarcinogenesis but do not enhance gap junctional intercellular communication" JPN. J. CANCER RES. (1997), 88(1), 12-17; ISSN: 0910-5050, 1997, XP002098384 see fig. 1 see abstract</p> <p>---</p> <p>VANDERHOEK, RACHAEL ET AL: "Bis(dimethylamino)-s-triazinyl antiinflammatory agents" J. MED. CHEM. (1973), 16(11), 1305-6 , 1973, XP002098385 see table 1</p> <p>---</p> <p>---</p>	1,3,4,23
X		1,3,4,23

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

^o Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

6 April 1999

16/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

International Application No	
PCT/US 98/26369	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 9249 Derwent Publications Ltd., London, GB; Class B03, AN 92-403404 XP002098387 -& JP 04 300874 A (TSUMURA & CO) , 23 October 1992 see column 5 see column 23 -----	1,3,4,23
X	DATABASE WPI Section Ch, Week 9249 Derwent Publications Ltd., London, GB; Class B03, AN 92-403379 XP002098388 -& JP 04 300832 A (TSUMURA & CO) , 23 October 1992 see column 4 see column 22 - column 23 -----	1,3,4,23
X	EP 0 563 386 A (NIPPON SHINYAKU CO LTD) 6 October 1993 see example 1 -----	1,3,6,9, 23
X	DE 29 19 496 A (DEGUSSA) 4 December 1980 see claims -----	1,3,4,23
X	EP 0 138 209 A (HITACHI LTD) 24 April 1985 see claim 1 -----	1,3,4,23
X	DE 44 23 138 A (HOECHST AG) 4 January 1996 see page 3, line 10 - line 23 -----	1,3,4,23
A	CHEMICAL ABSTRACTS, vol. 119, no. 3, 19 July 1993 Columbus, Ohio, US; abstract no. 20235, SATO, YASUFUMI ET AL: "Irsogladine is a potent inhibitor of angiogenesis" XP002098386 see abstract & FEBS LETT. (1993), 322(2), 155-8 ;ISSN: 0014-5793, 1993, -----	1,29,30

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/26369

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: **29, 30**

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 29, 30

are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.: **not applicable**

because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos.: not applicable

The search revealed such a large number of particularly relevant documents, in particular with regard to novelty, that the drafting of a comprehensive International Search Report is not feasible. The cited documents are considered as to form a representative sample of the revealed documents, duly taking into account their relevance with respect to the subject-matter as illustrated by the examples.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/26369

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0563386	A 06-10-1993	AU 9097991 A		22-07-1992
		WO 9211247 A		09-07-1992
DE 2919496	A 04-12-1980	AT 372070 B		25-08-1983
		AT 252580 A		15-01-1983
		BE 883282 A		13-11-1980
		BR 8002985 A		23-12-1980
		CA 1120477 A		23-03-1982
		CH 642363 A		13-04-1984
		DK 167280 A, B,		16-11-1980
		FR 2456735 A		12-12-1980
		GB 2056436 A, B		18-03-1981
		JP 1432631 C		24-03-1988
		JP 55162778 A		18-12-1980
		JP 62041593 B		03-09-1987
		NL 8001399 A		18-11-1980
		SE 435181 B		10-09-1984
		SE 8003652 A		16-11-1980
		US 4339578 A		13-07-1982
		US 4389333 A		21-06-1983
EP 0138209	A 24-04-1985	JP 1821311 C		10-02-1994
		JP 4037867 B		22-06-1992
		JP 61023666 A		01-02-1986
		JP 1861674 C		08-08-1994
		JP 2016935 B		18-04-1990
		JP 60082673 A		10-05-1985
		US 4555532 A		26-11-1985
DE 4423138	A 04-01-1996	CA 2153095 A		02-01-1996
		EP 0694571 A		31-01-1996
		JP 8100051 A		16-04-1996